export default [
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "paperqa-1.0.0",
    "date": "2023-04-09",
    "answer": "Bispecific CD38 antibodies bind to CD38, a protein expressed on the surface of multiple myeloma (MM) cells (Green2018, Cho2022 pages 14-15). These antibodies have two binding sites, one for CD38 and the other for CD3 on T cells, leading to T cell activation and subsequent killing of the myeloma cells (Cho2022 pages 14-15). In addition to blocking CD38, bispecific CD38 antibodies such as daratumumab and isatuximab also block immunosuppressive regulatory cells, including Treg, Breg, and myeloid-derived suppressor cells, leading to improved host-anti-tumor immunity (Cho2022 pages 1-2). Bispecific CD38 antibodies treat myeloma through pretargeted radioimmunotherapy (PRIT), which has demonstrated remarkable efficacy targeting tumor antigens (Green2018 pages 1-1). In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct demonstrated excellent blood clearance and tumor targeting, resulting in 100% complete remissions by day 12 in MM and NHL xenograft models, ultimately curing 80% of mice at optimal doses (Green2018 pages 1-1). However, the text does not provide information on the specific mechanisms of action of bispecific CD38 antibodies in newly diagnosed or relapsed/refractory patients (Verkleij2020 pages 1-1).",
    "sources": [
      {
        "key": "Verkleij2020 pages 1-1",
        "text": "Verkleij, Christie P.M., et al. \"T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.\" Oncotarget, vol. 11, no. 45, 2020, pp. 4076-4081."
      },
      {
        "key": "Cho2022 pages 14-15",
        "text": "Cho, Shih-Feng, et al. \"Bispecific antibodies in multiple myeloma treatment: A journey in progress.\" Frontiers in Oncology, vol. 12, 2022, pp. 1-14. DOI: 10.3389/fonc.2022.855946."
      },
      {
        "key": "Donk2018 pages 1-1",
        "text": "vandeDonk, N.W.C.J., and Saad Z. Usmani. \"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.\" Frontiers in Immunology, vol. 9, 2018, article 2134, doi:10.3389/\ufb01mmu.2018.02134."
      },
      {
        "key": "Green2018 pages 1-1",
        "text": "Green, Damian J., et al. \"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.\" Blood, vol. 131, no. 6, 2018, pp. 611-620."
      },
      {
        "key": "Cho2022 pages 1-2",
        "text": "Cho, Shih-Feng, et al. \"Bispecific antibodies in multiple myeloma treatment: A journey in progress.\" Frontiers in Oncology, vol. 12, 2022, pp. 1-14. DOI: 10.3389/fonc.2022.855946."
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "paperqa-1.0.0",
    "date": "2023-04-09",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods, including electric arc discharge, chemical vapor deposition, and laser ablation pyrolysis (Saravanan2010). The electric-arc technique can generate large quantities of single-walled carbon nanotubes (SWNTs) with similar characteristics to those obtained by laser ablation (Journet1997). In the electric arc-discharge apparatus, the arc is generated between two electrodes in a reactor under a helium atmosphere, and a mixture of a metallic catalyst and graphite powder is used (Journet1997). The growth mechanism for SWNTs must be independent of the details of the technique used to make them (Journet1997). The CoMoCAT method, a catalytic method, has been used to synthesize single-wall carbon nanotubes (SWCNTs) at a small-scale production rate of approximately 100 grams per day (Gavankar2015). The decrease in energy requirement for carbon nanotube synthesis is observed with increased level of manufacturing readiness for high-pressure carbon monoxide conversion, chemical vapor deposition, and arc discharge manufacturing (Gavankar2015). Other methods for large-scale production of carbon nanotubes include CO2-assisted growth, fluidized bed catalytic chemical vapor deposition, and the use of natural materials as catalysts (The2012). However, challenges in growing large quantities of pure, defect-free nanotubes have limited their widespread use (De6119). While there are several methods for mass production of ceramic matrix composites (CMCs) reinforced with carbon nanotubes (CNTs), including casting methods such as slip casting, tape casting, and gel casting, the text does not directly answer the question of what the methods are for mass production of CNTs (Meshalkin2020).",
    "sources": [
      {
        "key": "Journet1997 pages 1-1",
        "text": "Journet, C., Maser, W. K., Bernier, P., Loiseau, A., Lamy de la Chapelle, M., Lefrant, S., Deniard, P., Lee, R., & Fischer, J. E. (1997). Large-scale production of single-walled carbon nanotubes by the electric-arc technique. Nature, 388(6644), 756-758. doi: 10.1038/41972"
      },
      {
        "key": "De6119 pages 5-6",
        "text": "De Volder, Michael F. L., et al. \"Carbon Nanotubes: Present and Future Commercial Applications.\" Science, vol. 339, no. 6119, 2013, pp. 535-539."
      },
      {
        "key": "Gavankar2015 pages 4-5",
        "text": "Gavankar, Sheetal, Sangwon Suh, and Arturo A. Keller. \"The Role of Scale and Technology Maturity in Life Cycle Assessment of Emerging Technologies: A Case Study on Carbon Nanotubes.\" Journal of Industrial Ecology, vol. 19, no. 1, 2015, pp. 102-114. DOI: 10.1111/jiec.12175."
      },
      {
        "key": "The2012 pages 10-10",
        "text": "The citation for the article mentioned in the text would be: \n\nHuang, JiaQi, et al. \"A review of the large-scale production of carbon nanotubes: The practice of nanoscale process engineering.\" Chinese Science Bulletin, vol. 57, no. 2-3, 2012, pp. 157-166, doi: 10.1007/s11434-011-4879-z."
      },
      {
        "key": "Saravanan2010 pages 1-1",
        "text": "Saravanan, M.S. Senthil, et al. \"Techno-economics of carbon nanotubes produced by open air arc discharge method.\" International Journal of Engineering, Science and Technology, vol. 2, no. 5, 2010, pp. 100-108."
      },
      {
        "key": "Joselevich2008 pages 2-2",
        "text": "Joselevich, Ernesto, et al. \"Carbon Nanotube Synthesis and Organization.\" Carbon Nanotubes, edited by A. Jorio et al., vol. 111, Springer-Verlag Berlin Heidelberg, 2008, pp. 101-164."
      },
      {
        "key": "Meshalkin2020 pages 21-22",
        "text": "Meshalkin, Valerii P., and Alexey V. Belyakov. \"Methods Used for the Compaction and Molding of Ceramic Matrix Composites Reinforced with Carbon Nanotubes.\" Materials 13.17 (2020): 3831."
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "perplexity",
    "date": "2023-04-07",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods. One method is chemical vapor deposition (CVD), which utilizes high energy to atomize gaseous carbon sources such as methane, carbon monoxide, and acetylene[1]. Another method is laser ablation, which uses a high-power laser to vaporize a graphite source loaded with a metal catalyst[2]. Researchers at Western Michigan University\n have also developed a method for forming carbon nanotubes in a \nhigh-density, closely packed configuration, enabling their large-scale \nproduction[3]. Recently, MIT\n researchers have demonstrated that carbon nanotube transistors can be \nmade swiftly in commercial facilities, with the same equipment used to \nmanufacture silicon-based transistors[4].",
    "sources": [
      {
        "key": "1",
        "text": "https://www.britannica.com/science/carbon-nanotube"
      },
      {
        "key": "2",
        "text": "https://www.azonano.com/article.aspx?ArticleID=1108"
      },
      {
        "key": "3",
        "text": "https://wmich.edu/research/large-scale"
      },
      {
        "key": "4",
        "text": "https://news.mit.edu/2020/carbon-nanotube-transistors-factory-0601"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "perplexity",
    "date": "2023-04-07",
    "answer": "Bispecific CD38\n antibodies are designed to bind to both CD38, a protein found on the \nsurface of multiple myeloma (MM) cells, and CD3, a protein found on T \ncells[1][2]. By binding to both CD38 and CD3, bispecific CD38 antibodies activate T cells to attack and kill MM cells[1][3]. This mechanism of action is similar to that of other anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab[4].\n Bispecific CD38 antibodies are a novel immunotherapeutic modality that \nhas shown impressive preliminary efficacy in heavily treated MM patients[1]. They are expected to become an integral part of the MM treatment paradigm in the near future[1].",
    "sources": [
      {
        "key": "1",
        "text": "https://aacrjournals.org/bloodcancerdiscov/article/2/5/423/665839/Bispecific-Antibodies-in-Multiple-Myeloma-Present"
      },
      {
        "key": "2",
        "text": "https://www.news-medical.net/whitepaper/20210817/Targeting-CD38CD3-in-the-immunotherapy-of-multiple-myeloma.aspx"
      },
      {
        "key": "3",
        "text": "https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1814253"
      },
      {
        "key": "4",
        "text": "https://ashpublications.org/blood/article/138/Supplement%201/1580/480536/The-Role-of-CD38-in-Multiple-Myeloma-Cell-Biology"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "scite",
    "date": "2023-04-09",
    "answer": "As of 2022, there are limited treatment options available for amyotrophic lateral sclerosis (ALS) patients [1]. The only two modestly efficacious disease-modifying drugs available are riluzole and edaravone [1][6]. However, there are several therapeutics being researched for ALS treatment. Cell-based therapy has been proposed as an ultimate source for regeneration of motor neurons (MNs) [2][4]. Recent completion of non-autologous fetal spinal stem cell transplant to ALS patients brought renewed hope for further human trials to cure the disease [2]. Autologous somatic stem cell-based human trials are now in track to reveal the outcome of the ongoing trials [2]. Furthermore, induced pluripotent stem cell (iPSC)-based ALS disease drug screen and autologous cell transplant options will broaden therapeutic options [2]. Astrocyte-based cell therapy is another potential treatment for ALS [3]. Embryonic stem cell-derived astrocytes behave as highly trophic \u201cyoung astrocytes\u201d, being able to delay disease onset and prolong survival when injected intrathecally in murine models of ALS overexpressing the SOD1G93A mutation [3]. The safety and therapeutic potential of these cells are currently being evaluated in a clinical trial in ALS patients [3]. Human umbilical cord blood (hUCB) cells may be a promising new treatment for ALS, mainly by providing a protective microenvironment for motor neuron survival [5]. Among multiple advantages, hUCB cells' production of various anti-inflammatory/growth/trophic factors makes them an attractive cell source for ALS therapy [5]. Biodistribution and optimal hUCB cell dose for transplantation have been determined in current ALS clinical trials [5]. In addition to cell-based therapy, positron emission tomography (PET) imaging has promise as a biomarker for ALS because it permits visualization of central nervous system (CNS) pathology in individuals living with ALS [1]. PET radioligands that target a variety of potential pathophysiological mechanisms\u2014including cerebral metabolism, neuroinflammation, neuronal dysfunction, and oxidative stress\u2014has enabled dynamic interrogation of molecular changes in ALS, in both natural history studies and human clinical trials [1]. In conclusion, while there are limited treatment options available for ALS patients, there are several promising therapeutics being researched, including cell-based therapy, astrocyte-based cell therapy, and human umbilical cord blood cells. PET imaging also has potential as a diagnostic biomarker for ALS.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.frontiersin.org/articles/10.3389/fneur.2019.00135/full"
      },
      {
        "key": "2",
        "text": "https://www.en-journal.org/journal/view.html?doi=10.5607/en.2014.23.3.207"
      },
      {
        "key": "3",
        "text": "https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-1006-y"
      },
      {
        "key": "4",
        "text": "10.4172/2325-9620.1000118"
      },
      {
        "key": "5",
        "text": "https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1323862"
      },
      {
        "key": "6",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/med.21528"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "perplexity",
    "date": "2023-04-09",
    "answer": "As of 2022, there are six FDA-approved drugs for treating ALS and its symptoms, including RELYVRIO, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta[1]. There are also several therapies being researched for ALS treatment. For example, an experimental drug is being tested in a global phase 3 clinical trial based on promising results from a study at Columbia University[2]. Tofersen is another therapy being investigated for treating ALS caused by mutations in the SOD1 gene[3]. Additionally, NU-9 is a potential ALS treatment that has shown to be more effective than existing FDA-approved drugs when given in combination with riluzole and edaravone[4]. The ALS Association is currently funding 121 active research projects in 12 countries with $44 million committed to research[5].",
    "sources": [
      {
        "key": "1",
        "text": "https://www.als.org/navigating-als/living-with-als/fda-approved-drugs"
      },
      {
        "key": "2",
        "text": "https://www.cuimc.columbia.edu/news/promising-als-therapy-moves-closer-clinic"
      },
      {
        "key": "3",
        "text": "https://www.ajmc.com/view/overview-of-current-and-emerging-therapies-for-amyotrophic-lateral-sclerosis"
      },
      {
        "key": "4",
        "text": "https://news.northwestern.edu/stories/2022/05/new-als-drug-is-more-effective-than-existing-ones/"
      },
      {
        "key": "5",
        "text": "https://www.als.org/2022-year-review"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "There are several ways to cluster protein structures output from a molecular dynamics trajectory. One common method is cluster analysis, which involves grouping similar conformations together[1]. Clustering algorithms have been widely used to reduce the dimensionality of molecular dynamics trajectories[2]. Principal Component Analysis (PCA) is another method that can be used to cluster protein structures[3]. The goal of clustering is to partition data so that data points inside a cluster are more similar to each other than they are to points outside a cluster[1]. Structural features from the substrate-binding cavity of the receptor can also be used to optimize docking experiments on a cloud[2].",
    "sources": [
      {
        "key": "1",
        "text": "https://amberhub.chpc.utah.edu/clustering-a-protein-trajectory/"
      },
      {
        "key": "2",
        "text": "https://pubmed.ncbi.nlm.nih.gov/25873944/"
      },
      {
        "key": "3",
        "text": "https://www.nature.com/articles/s41598-022-13714-z"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "To cluster protein structures output from a molecular dynamics trajectory, several methods can be used. One such method is fuzzy clustering, which can locate classes of similar three-dimensional conformations explored during a molecular dynamics simulation [1]. Another method is quantum clustering, which can objectively cluster the conformations sampled by molecular dynamics simulations performed on different ligand-bound structures of the protein [2]. K-means clustering is another widely used clustering algorithm that can be implemented in the protein essential dynamics subspace defined by principal component analysis on the molecular dynamics trajectory [4]. In addition to clustering, visualizing the solvent paths entering and leaving cavities of the protein can also be useful in studying the route and dynamics of the exchange of tightly bound internal water molecules with the bulk solvent [3]. Overall, the choice of clustering method depends on the specific research question and the type of data being analyzed. It is important to choose a method that is appropriate for the data and can provide meaningful insights into the protein structures.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/prot.340140211"
      },
      {
        "key": "2",
        "text": "https://pubs.rsc.org/en/content/articlelanding/2011/MB/c1mb05038a"
      },
      {
        "key": "3",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/j.1467-8659.2008.01227.x"
      },
      {
        "key": "4",
        "text": "https://www.worldscientific.com/doi/abs/10.1142/S0219633613410083"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, there are several factors to consider. The diene component must be able to assume an s-cis conformation, and electron-withdrawing groups on the dienophile facilitate the reaction. Electron-donating groups on the diene also facilitate the reaction[1]. Controlling the reaction to select for the endo product relies on changing the HOMO and/or LUMO of the system[2]. The reactivity and stereoselectivity in the Lewis acid-catalyzed Diels-Alder reaction are controlled by a combination of several interaction terms[3]. Physical factors leading to the computed periodic reactivity trend upon going from the uncatalyzed to the bond-catalyzed Diels-Alder reactions can be analyzed and compared[4]. Additionally, external electric fields can be used as a catalyst to manipulate the reactivity and selectivity of the reaction[5].",
    "sources": [
      {
        "key": "1",
        "text": "https://chem.libretexts.org/Courses/University_of_Illinois_Springfield/UIS%3A_CHE_269_(Morsch_and_Andrews)/Chapters/Chapter_16%3A_Conjugation%2C_Resonance%2C_and_Dienes/16.11_Rules_of_the_Diels%E2%80%93Alder_Reaction"
      },
      {
        "key": "2",
        "text": "https://chem.libretexts.org/Courses/University_of_California_Davis/UCD_Chem_231A%3A_Methods_of_Organic_Synthesis/Text/Diels-Alder_Reaction"
      },
      {
        "key": "3",
        "text": "https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/open.202000112"
      },
      {
        "key": "4",
        "text": "https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/chem.202100522"
      },
      {
        "key": "5",
        "text": "https://www.nature.com/articles/nature16989/"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, several factors should be considered. The nature of the catalyst can affect the reaction rate, selectivity, and yield of the product. The following are some factors to consider when selecting a catalyst for a Diels-Alder reaction: 1. Lewis acidity: Catalysts with high Lewis acidity can activate the dienophile and diene, leading to faster reaction rates and higher yields. For example, silica and alumina modified by Lewis acids have been shown to be efficient catalysts in Diels-Alder reactions of carbonyl-containing dienophiles [2]. 2. Chirality: Chiral catalysts can induce enantioselectivity in the reaction, leading to the formation of a single enantiomer of the product. For example, oxazaborolidinone-catalyzed enantioselective Diels-Alder reactions have been reported [1]. 3. Stability: Catalysts that are stable under the reaction conditions can be reused, reducing the cost of the reaction. For example, the catalyst SiO2\u00b7AlClEt2 retains a great deal of its catalytic activity when recovered or stored in the open air for one month [2]. 4. Endo/exo selectivity: Catalysts can influence the endo/exo selectivity of the reaction, leading to the formation of either endo or exo adducts. For example, allo-threonine-derived O-acyl-B-phenyl-oxazaborolidinones are highly enantioselective Lewis acid catalysts for the Diels-Alder reaction of simple acyclic enone dienophiles, expanding the scope of ketone dienophiles and dienes [1]. 5. Reactivity: Catalysts can affect the reactivity of the dienophile and diene, leading to the formation of the desired product. For example, carbocations such as Ph3C+ have been shown to be extremely efficient, mild, and selective Lewis acid catalysts for Diels-Alder reactions [3]. In summary, when selecting a catalyst for a Diels-Alder reaction, factors such as Lewis acidity, chirality, stability, endo/exo selectivity, and reactivity should be considered. The choice of catalyst can significantly affect the reaction rate, selectivity, and yield of the product [1]. [2][3]",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.acs.org/doi/10.1021/jo702043g"
      },
      {
        "key": "2",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/chin.199337096"
      },
      {
        "key": "3",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/chin.201427035"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Based on the provided search results, selfies and smiles are both used as molecular representations for deep learning. SMILES is a popular string-based representation that has been used in computational chemistry for decades[1][2]. SELFIES is a newer representation that has been shown to be more diverse and robust than SMILES[3][1][4]. Geometric representations are also becoming more important in molecular deep learning[5]. Therefore, the choice between selfies or smiles as a better representation of molecules for deep learning may depend on the specific application and the type of information that needs to be extracted from the molecular structure.\n",
    "sources": [
      {
        "key": "1",
        "text": "https://arxiv.org/abs/2204.00056"
      },
      {
        "key": "2",
        "text": "https://iopscience.iop.org/article/10.1088/2632-2153/aba947"
      },
      {
        "key": "3",
        "text": "https://arxiv.org/abs/1905.13741"
      },
      {
        "key": "4",
        "text": "https://deepai.org/publication/selfies-and-the-future-of-molecular-string-representations"
      },
      {
        "key": "5",
        "text": "https://www.nature.com/articles/s42256-021-00418-8"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Deep learning has brought a dramatic development in molecular property prediction that is crucial in the field of drug discovery using various representations such as fingerprints, SMILES, and graphs [1]. SMILES is commonly used in chemistry applications with SMILES sequences [2]. However, SMILES has a limitation in that it is hard to reflect chemical properties [1]. SELFIEs, on the other hand, have been shown to be superior to SMILES for tasks such as Optical Chemical Entity Recognition [4][5]. SELFIEs match the representation used in MACCS, which is commonly used in regression models [2]. However, using SELFIEs over SMILES does not necessarily translate to better supervised learning performance [2]. In addition, there exists a performance gap between the existing unpretrained SMILES-based models and graph-based models at large-scale benchmark results, while pretrain models are resource-demanding at training [3]. Therefore, it can be concluded that SELFIEs are a better representation of molecules for deep learning than SMILES, but the choice of representation depends on the specific task and the availability of resources.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/s41598-021-90259-7"
      },
      {
        "key": "2",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/613268f0d5f0803706ba0c79"
      },
      {
        "key": "3",
        "text": "https://arxiv.org/abs/2112.13305"
      },
      {
        "key": "4",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/60c756c2567dfe48eaec654c"
      },
      {
        "key": "5",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/60c75681567dfe722dec64d6"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "There are several promising targets for Alzheimer's disease beyond Abeta. These include:\n\u2022 Lecanemab, a medicine that slows cognitive decline in people with early Alzheimer's disease by 27% [1]\n\u2022 Immune cells, toxic protein tangles, and brain waves[2]\n\u2022 Tau proteins, which are a promising target for passive immunotherapy[3]\n\u2022 APOE4, pericytes, and Cyclophilin A, which have been shown to accelerate blood-brain barrier breakdown and are potential targets for treatment[4]\n\u2022 Immunotherapies based on other targets such as tau, microglia, and the gut-brain axis are also under development[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780"
      },
      {
        "key": "2",
        "text": "https://www.npr.org/sections/health-shots/2021/08/09/1026207499/new-treatments-look-for-ways-to-protect-the-brain-from-alzheimers"
      },
      {
        "key": "3",
        "text": "https://pubmed.ncbi.nlm.nih.gov/32682954/"
      },
      {
        "key": "4",
        "text": "https://www.sciencedaily.com/releases/2021/06/210614131220.htm"
      },
      {
        "key": "5",
        "text": "https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-022-00292-3"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Alzheimer's disease is a multifactorial neurodegenerative disorder with many drug targets contributing to its etiology [3]. While increased production and deposition of amyloid beta-protein (Abeta) are believed to be key pathogenic events in Alzheimer's disease, other potential therapeutic targets have been identified [1][2][4]. Glycogen synthase kinase-3 beta (GSK-3\u03b2) and cyclin-dependent kinase 5 (CDK5) have been identified as being involved in the pathological hyperphosphorylation of tau proteins, which leads to the formation of neurofibrillary tangles and causes Alzheimer's disease [3]. Inhibition of p38 mitogen-activated protein kinase (MAPK) is also considered a promising strategy for the treatment of Alzheimer's disease [4]. Additionally, peripheral blood biomarkers offer a promising, non-intrusive mechanism for early Alzheimer's disease diagnosis [5]. The corpus callosum has also been identified as a novel target for human neural stem cell transplantation in transgenic Alzheimer's disease mouse models [6]. Therefore, potential therapeutic targets for Alzheimer's disease, other than Abeta, include GSK-3\u03b2, CDK5, p38 MAPK, peripheral blood biomarkers, and the corpus callosum.",
    "sources": [
      {
        "key": "1",
        "text": "https://academic.oup.com/hmg/article/18/23/4492/664197"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/acs.joc.1c01970"
      },
      {
        "key": "3",
        "text": "https://www.oncotarget.com/article/15085/text/"
      },
      {
        "key": "4",
        "text": "https://www.mdpi.com/1420-3049/22/8/1287"
      },
      {
        "key": "5",
        "text": "https://www.mdpi.com/2073-4425/12/11/1794"
      },
      {
        "key": "6",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/acn3.443"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Salamanders can breathe through their gills, lungs, skin, mouth, and throat. The process of breathing can differ from type to type of salamanders. Some salamanders breathe through their gills, while others breathe through their lungs. Salamanders primarily rely on their skin for respiration, which is thin and permeable, allowing oxygen to diffuse into their bloodstream and carbon dioxide to diffuse out. Salamanders that live on land lose their gills as they grow older. Salamander larvae breathe through their gills, while adult salamanders such as the lungless salamanders breathe through their skin and the lining of their mouth, which is called buccopharyngeal respiration. [1][2][3][4][5]",
    "sources": [
      {
        "key": "1",
        "text": "https://k12.libretexts.org/Bookshelves/Science_and_Technology/Life_Science_for_Middle_School_(CK-12)/10%3A_Vertebrates/10.8%3A_Salamanders"
      },
      {
        "key": "2",
        "text": "https://acuariopets.com/how-do-salamanders-breathe/"
      },
      {
        "key": "3",
        "text": "https://amphibianplanet.com/how-salamanders-breathe/"
      },
      {
        "key": "4",
        "text": "https://www.britannica.com/science/respiratory-system/Amphibians"
      },
      {
        "key": "5",
        "text": "https://www.burkemuseum.org/collections-and-research/biology/herpetology/all-about-amphibians/all-about-amphibians"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Salamanders possess a pair of lungs for active air breathing, but the lung respiration is fully operational only during the late stage of development, particularly after metamorphosis. Larval salamanders mainly exchange air through the gills and skin, thus sparing the developing lungs [1]. Therefore, salamanders breathe through their skin and gills during their larval stage. However, after metamorphosis, they switch to breathing through their lungs [1].",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/cpr.13369"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Several methods can be used to explain predictions from black box models in chemistry. One approach is to use explainable AI (XAI) to interpret the entire model at once or to explain an individual prediction[1][2][3]. Another method is to estimate the causal effect of each input variable or feature on the output variable[4]. Some popular ways to explain black box models include using partial dependence plots, permutation feature importance, and SHAP values[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://engineering.dynatrace.com/blog/understanding-black-box-ml-models-with-explainable-ai/"
      },
      {
        "key": "2",
        "text": "https://www.zdnet.com/article/explainable-ai-artificial-intelligence-a-guide-for-making-black-box-machine-learning-models-explainable/"
      },
      {
        "key": "3",
        "text": "https://link.springer.com/chapter/10.1007/978-3-030-79108-7_8"
      },
      {
        "key": "4",
        "text": "https://ist.psu.edu/research/projects/black-box-predictive-models"
      },
      {
        "key": "5",
        "text": "https://www.elderresearch.com/blog/how-and-why-to-interpret-black-box-models/"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Black box models in chemistry, such as deep learning models, lack interpretability, which can make chemists skeptical of their use in decision making [1][2]. Explainable artificial intelligence (XAI) is a branch of AI that addresses this drawback by providing tools to interpret black box models and their predictions [1][2]. XAI methods like chemical counterfactuals and descriptor explanations can explain deep learning predictions while giving insight into structure-property relationships [1][2]. XAI methods can also be used to predict molecular properties and optimize molecular properties and synthetic pathways [3][4]. In addition, machine learning models can be combined with quantum chemistry to speed up the calculation of molecular properties while maintaining accuracy [5].",
    "sources": [
      {
        "key": "1",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/639222a114d92d7cd6a65e90"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jctc.2c01235"
      },
      {
        "key": "3",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/63e699bafcfb27a31f8dd492"
      },
      {
        "key": "4",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01789"
      },
      {
        "key": "5",
        "text": "https://pubs.acs.org/doi/abs/10.1021/cen-09714-scicon6"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "The input materials and energy required to use microorganisms for the synthesis of plastics depend on the specific process used. However, some general information can be found in the provided search results. For example, microbial electrosynthesis can reduce energy input compared to using water as an electron donor[1]. Photosynthesis is a process that uses light energy to construct glucose molecules from water and carbon dioxide, which can provide energy and fixed carbon for organisms[2][3]. Some bio-based monomers and polymers can be synthesized using microbes[4]. Synthetic biology has the potential to enable sustainable manufacturing of chemicals, including plastics, using microbes[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/nrmicro2422/"
      },
      {
        "key": "2",
        "text": "https://www.britannica.com/science/photosynthesis"
      },
      {
        "key": "3",
        "text": "https://www.khanacademy.org/science/ap-biology/cellular-energetics/photosynthesis/a/intro-to-photosynthesis"
      },
      {
        "key": "4",
        "text": "https://www.sciencedirect.com/science/article/abs/pii/S096085242101498X"
      },
      {
        "key": "5",
        "text": "https://www.nature.com/articles/s41587-022-01248-8"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Microbial synthesis of plastics from renewable resources has attracted considerable attention in recent years [1]. Polyesters such as polyethylene terephthalate (PET) are amenable to biological degradation due to the action of microbial polyester hydrolases [2]. The hydrolysis products obtained from PET can be used for the synthesis of novel PET as well as become a potential carbon source for microorganisms [2]. Microorganisms and biomass can also be used for the synthesis of the constituent monomers of PET from renewable sources [2]. The use of microalgal biomass as a feedstock for PHA synthesis presents a low-cost solution [3]. Activated sludge processes can be used for treating wastewater and producing PHAs [4]. The energy required for microbial synthesis of plastics can be generated from renewable resources [1]. Therefore, the materials required input to use microorganisms for synthesis of plastics include renewable carbohydrate sources, microorganisms, biomass, and energy from renewable resources.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/anie.200301655"
      },
      {
        "key": "2",
        "text": "https://www.mdpi.com/2073-4425/10/5/373"
      },
      {
        "key": "3",
        "text": "https://www.frontiersin.org/articles/10.3389/fbioe.2022.879476/full"
      },
      {
        "key": "4",
        "text": "https://www.mrforum.com/product/9781644901335-6/"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Birds flock together for various reasons, including safety, warmth, and finding food[1][2][3][4]. Flocking can help birds avoid predators, share body heat, and locate food sources more efficiently. Flocking behavior can also be a way for birds to socialize and communicate with each other. The coordinated movements of birds in a flock are thought to be the result of each bird following simple rules based on the movements of its neighbors[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://theconversation.com/why-do-flocks-of-birds-swoop-and-swirl-together-in-the-sky-a-biologist-explains-the-science-of-murmurations-176194"
      },
      {
        "key": "2",
        "text": "https://www.psychologytoday.com/us/blog/creating-connection/202012/why-do-birds-flock-together"
      },
      {
        "key": "3",
        "text": "https://news.yahoo.com/why-flocks-black-birds-suddenly-160130498.html?fr=sycsrp_catchall"
      },
      {
        "key": "4",
        "text": "https://www.columbia-audubon.org/birds-in-big-numbers-flocks-of-blackbirds-and-starlings/"
      },
      {
        "key": "5",
        "text": "https://earthsky.org/earth/how-do-flocking-birds-move-in-unison/"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Birds flock for various reasons, including foraging efficiency, predation avoidance, and social behavior [1]. Mixed-species flocks of birds involve species with different roles and foraging strategies and are ubiquitous in forest environments [1]. The diversity of foraging strategies occurring in a mixed flock reflects the diversity of participant species [1]. One of the main benefits of participating in mixed-species flocks is increased foraging efficiency [1]. However, feeding benefits remain under debate, probably because not all participants receive this benefit in the same way [1]. Species roles can broadly be categorized into leaders that attract others to form the flock, as well as lead the flock's movement; and follower species [1]. The predator avoidance hypothesis suggests that birds in mixed flocks increase their vigilance levels and decrease their predation risk [2]. The foraging efficiency hypothesis suggests that birds in mixed flocks increase their foraging efficiency and/or can spend more time feeding and less time looking out for predators [3]. The social behavior hypothesis suggests that birds flock for social reasons, such as to find mates or to learn from other birds [4]. In conclusion, birds flock for various reasons, including foraging efficiency, predation avoidance, and social behavior, and mixed-species flocks involve species with different roles and foraging strategies [1].",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/ibi.13162"
      },
      {
        "key": "2",
        "text": "https://link.springer.com/article/10.1007/s10164-004-0124-4"
      },
      {
        "key": "3",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/btp.12551"
      },
      {
        "key": "4",
        "text": "https://www.tandfonline.com/doi/abs/10.1080/00306525.1989.9639611"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods. One method is the thermal decomposition of a ferrocenyl compound in the presence of a multi(ethynyl)aromatic compound [1]. Another method is the use of an arc-jet plasma of high temperature to decompose methane [2]. Ethanol thermal reduction process can also be used to synthesize carbon nanotubes on a large scale [3]. The flame method is another simple method that can be used to synthesize carbon nanotubes [4]. Large-scale production of carbon nanotubes can also be achieved by using millimeter-diameter spheres as growth substrates [5]. The method described in [1] permits the large-scale production of carbon nanotubes in a shaped, solid configuration. The carbon nanotubes form under atmospheric pressure during the carbonization process above 500 \u00b0C in the carbonaceous solid. The Fe atoms, nanoclusters, and/or nanoparticles formed from the decomposition of the ferrocenyl compound are the key to the formation of the carbon nanotubes in the developing carbonaceous solid by reacting with the developing polycondensed aromatic ring system. The arc-jet plasma process described in [2] is continuous and easily scalable, making it a promising technique for the large-scale commercial production of carbon nanotubes. The optimal operating condition for the production of high purity multi-walled carbon nanotubes was found in this study. The ethanol thermal reduction process described in [3] uses ethanol as the carbon source and magnesium as the reductant. This method avoids the use of toxic or corrosive reagents and can potentially be applied on the scale of industrial production. The flame method described in [4] is a new and simple method that may have the possibility of large-scale mass production for the synthesis of carbon nanotubes. It needs not the vacuum environment and carbon nanotubes can be captured at the normal atmospheric pressure. The use of millimeter-diameter spheres as growth substrates for the large scale and continuous production of aligned carbon nanotube arrays is reported in [5]. This technique is more productive than the conventional process on flat wafers because of the higher available growth surface and the good fluidity of the spherical substrates. In conclusion, there are various methods for the large-scale production of carbon nanotubes, including thermal decomposition, arc-jet plasma, ethanol thermal reduction, flame method, and the use of millimeter-diameter spheres as growth substrates. Each method has its advantages and disadvantages, and the choice of method depends on the specific application and requirements.",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.acs.org/doi/10.1021/jp0665527"
      },
      {
        "key": "2",
        "text": "https://www.sciencedirect.com/science/article/abs/pii/S1567173905001926?via%3Dihub"
      },
      {
        "key": "3",
        "text": "https://pubs.acs.org/doi/10.1021/ja035763b"
      },
      {
        "key": "4",
        "text": "https://www.scientific.net/AMR.1048.383"
      },
      {
        "key": "5",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/cvde.200704249"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "CD38 is a transmembrane glycoprotein that is highly expressed in almost all myeloma cells, making it an attractive treatment target [1]. Bispecific antibodies targeting CD38 and CD3 have been developed as a therapeutic strategy for multiple myeloma [2]. These antibodies recruit effector T cells to CD38-expressing myeloma cells and induce antibody-dependent cell-mediated cytotoxicity (ADCC) [2]. Anti-CD38 monoclonal antibodies have been approved for first-line treatment in non-transplantable multiple myeloma patients [1]. Isatuximab-irfc and daratumumab are examples of anti-CD38 monoclonal antibodies that have been approved for the treatment of multiple myeloma [4]. However, it has been found that anti-CD38 monoclonal antibodies bind to CD38 on red blood cells (RBCs) and cause pan agglutination in indirect antiglobulin test (IAT), resulting in false positives of IAT and thereby interfering with blood bank testing and leading to the delay of further diagnosis and treatment [1]. Bispecific CD38 antibodies have the potential to overcome the limitations of current therapies in patients with multiple myeloma by triggering the complete elimination of malignant multiple myeloma cells in patients, including low-expressing cells that may evade daratumumab, with the potential to induce profound clinical responses [3]. In conclusion, bispecific CD38 antibodies bind to CD38 on myeloma cells and recruit effector T cells to induce ADCC, making them an effective therapeutic strategy for multiple myeloma.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/jcla.23832"
      },
      {
        "key": "2",
        "text": "https://ashpublications.org/blood/article/128/22/2097/100388/The-Trifunctional-Antibody-tri-31C2-Targeting-CD38"
      },
      {
        "key": "3",
        "text": "https://aacrjournals.org/clincancerres/article/25/13/3921/81953/Targeting-Multiple-Myeloma-with-AMG-424-a-Novel"
      },
      {
        "key": "4",
        "text": "https://jamanetwork.com/journals/jama/article-abstract/2764168?utm_campaign=scite&utm_source=scite&utm_medium=referral"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "paperqa-1.1.1",
    "date": "2023-04-11",
    "answer": "Bispecific CD38 antibodies are a promising immunotherapy for the treatment of multiple myeloma. These antibodies work by redirecting T cells to attack CD38-expressing myeloma cells (Shih2022). CD38 is a promising target for immunotherapy in multiple myeloma due to its high expression on myeloma cells and its role in regulating the immune system (Shih2022). Specific examples of CD38-targeting bispecific antibodies mentioned in the literature include BI38-3, MEDI2228, and AMG 424 (Shih2022). However, neither Shih2022 nor Verkleij4076 provide a direct quote that specifically answers the question of what bispecific CD38 antibodies bind to and how they treat myeloma. \n\nThat being said, other sources suggest that CD38-targeting antibodies, such as daratumumab or isatuximab, are used in combination therapy and can be effective in eliminating myeloma cells (Verkleij4076). These antibodies bind to CD38 on the surface of myeloma cells, leading to antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Palumbo2016). ADCC involves the binding of the antibody to the target cell, which then activates immune cells to attack and kill the target cell. CDC involves the activation of the complement system, which leads to the formation of a membrane attack complex that can lyse the target cell (Palumbo2016). \n\nIn summary, while the literature suggests that bispecific CD38 antibodies are a promising immunotherapy for the treatment of multiple myeloma, the specific mechanism of action of these antibodies is not provided in the sources available. However, other CD38-targeting antibodies, such as daratumumab or isatuximab, are known to bind to CD38 on the surface of myeloma cells and induce ADCC and CDC, leading to the elimination of myeloma cells (Verkleij4076, Palumbo2016). \n\nSources: \n- Shih2022 pages 14-15\n- Verkleij4076 pages 1-1\n- Palumbo2016",
    "sources": [
      {
        "key": "Shih2022 pages 14-15",
        "text": "Shih-Feng Cho, Tsung-Jang Yeh, K. Anderson, and Y. Tai. Bispecific antibodies in multiple myeloma treatment: a journey in progress. Frontiers in Oncology, 2022."
      },
      {
        "key": "Verkleij4076 pages 1-1",
        "text": "C. P. Verkleij, K. Frerichs, M. Broekmans, S. Absalah, P. W. Maas-Bosman, Sandy Kruyswijk, I. Nijhof, T. Mutis, S. Zweegman, and N. V. D. van de Donk. T-cell redirecting bispecific antibodies targeting bcma for the treatment of multiple myeloma. Oncotarget, 11:4076 - 4081, 2020."
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "paperqa-1.1.1",
    "date": "2023-04-11",
    "answer": "As of 2022, several antisense therapeutics are being researched for ALS, including BIIB105, an antisense therapeutic designed to decrease ATXN2 expression, which has demonstrated increased survival in a mouse model of TDP-43 ALS and is currently undergoing phase I clinical evaluation (Roberts2022 pages 11-12). Additionally, an investigational FUS-targeted AO (ION363) has been administered to one patient, and a phase I-III clinical trial for this drug has recently been announced (Roberts2022 pages 11-12). However, the C9orf72 targeting AO BIIB078 was recently evaluated in phase I clinical trial and designed to selectively target C9orf72 transcripts with repeat expansions, but the trial was terminated in March 2022 due to not meeting primary or secondary endpoints (Roberts2022 pages 11-12). Alternative AO strategies and sequences targeting C9orf72 are currently undergoing clinical evaluation, including WVE-004 and a\ufb01nersen (Roberts2022 pages 11-12). Tofersen (BIIB067) is an antisense therapy designed to target and reduce SOD1 mRNA, currently under evaluation in phase III studies for patients carrying pathogenic SOD1 mutations (Roberts2022 pages 11-12).\n\nIn addition to antisense therapeutics, other therapeutic options for ALS have historically focused on slowing disease progression and providing symptomatic treatments to improve patient quality of life, including pain management, therapeutic exercise, and physiotherapy (Roberts2022 pages 9-10). Riluzole and edaravone are the only two drugs approved by the FDA for ALS treatment, with riluzole being the most widely used (Roberts2022 pages 9-10). However, their efficacy remains controversial, and more than 70 randomized drug trials in ALS patients have shown little beneficial effect on patient survival (Roberts2022 pages 9-10).\n\nWhile the article by Agrawal2022 does not provide information on available or being researched therapeutics for ALS in 2022, the article by Belgin2022 discusses past and future therapeutic strategies for the treatment of ALS, including pharmacological and non-pharmacological approaches, as well as emerging therapies such as gene therapy and stem cell therapy (Belgin2022 pages 1-1). The authors emphasize the multifaceted nature of ALS affected by many pathological mechanisms and the need for further research to develop effective treatments for ALS (Belgin2022 pages 1-1).\n\nThe article by Tereza2020 discusses various therapeutic approaches for ALS, including gene therapy, cell-based therapies, and neurotrophic factors (Tereza2020 pages 25-26). One gene therapy, VM202, has been shown to be safe and effective in reducing ALSFRS-R decline (Tereza2020 pages 25-26). Another compound, SynCav1, has shown promise in improving motor function and survival in preclinical ALS mouse models (Tereza2020 pages 25-26). Cell-based therapies, such as astrocyte-based therapies and the transplantation of human glial restricted progenitor cells, have also shown promise in preclinical and clinical trials (Tereza2020 pages 25-26). Kadimastem Ltd. has reported promising interim results in a Phase 1/2a clinical trial using AstroRx\u00ae cells, which contain functional healthy astrocytes derived from human embryonic stem cells (Tereza2020 pages 25-26). A Phase 1/2a open-label study will also be initiated in 2020 to investigate the safety of the transplantation of human glial restricted progenitor cells into the spinal cord of ALS patients (Tereza2020 pages 25-26).",
    "sources": [
      {
        "key": "Roberts2022 pages 11-12",
        "text": "B. Roberts, F. Theunissen, F. Mastaglia, P. Akkari, and L. L. Flynn. Synucleinopathy in amyotrophic lateral sclerosis: a potential avenue for antisense therapeutics? International Journal of Molecular Sciences, 2022."
      },
      {
        "key": "Roberts2022 pages 9-10",
        "text": "B. Roberts, F. Theunissen, F. Mastaglia, P. Akkari, and L. L. Flynn. Synucleinopathy in amyotrophic lateral sclerosis: a potential avenue for antisense therapeutics? International Journal of Molecular Sciences, 2022."
      },
      {
        "key": "Agrawal2022 pages 22-22",
        "text": "I. Agrawal, Yong Shan Lim, Shi\u2010Yan Ng, and Shuo-Chien Ling. Deciphering lipid dysregulation in als: from mechanisms to translational medicine. Translational Neurodegeneration, 2022."
      },
      {
        "key": "Belgin2022 pages 1-1",
        "text": "Belgin Sever, Halil I. Ciftci, H. Demirci, Hilal Sever, Firdevs Ocak, B. Yulug, Hiroshi Tateishi, T. Tateishi, M. Otsuka, M. Fujita, and A. Ba\u015fak. Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis. International Journal of Molecular Sciences, 2022."
      },
      {
        "key": "Tereza2020 pages 25-26",
        "text": "Tereza Filipi, Z. Hermanova, J. Tureckova, Ond\u0159ej Va\u0148\u00e1tko, and M. And\u011brov\u00e1. Glial cells\u2014the strategic targets in amyotrophic lateral sclerosis treatment. Journal of Clinical Medicine, 2020."
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "paperqa-1.1.1",
    "date": "2023-04-11",
    "answer": "I cannot answer",
    "sources": [
      {
        "key": "Urbanek7669 pages 8-8",
        "text": "A. Urbanek, W. Rymowicz, and A. Miro\u0144czuk. Degradation of plastics and plastic-degrading bacteria in cold marine habitats. Applied Microbiology and Biotechnology, 102:7669 - 7678, 2018."
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "paperqa-1.1.1",
    "date": "2023-04-11",
    "answer": "Several potential targets for Alzheimer's disease beyond ABeta have been identified in the literature. Hampel5481 pages 22-23 discusses genetic loci such as TREM2, SORL1, and ABCA7, as well as common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, and CD2AP. Loss-of-function variants in ABCA7 are also mentioned as a risk factor for Alzheimer's disease. Additionally, the article discusses the importance of identifying preclinical stages of Alzheimer's disease and the potential use of amyloid positron emission tomography for staging beta-amyloid pathology. Chandra5424 pages 17-17 suggests that tau protein and neuroinflammation may be alternative targets for Alzheimer's disease, in addition to amyloid-beta, and cites several studies investigating the use of PET imaging to detect tau protein and neuroinflammation in patients with Alzheimer's disease and mild cognitive impairment. Chen2022 pages 4-5 mentions signaling pathways that induce cerebral blood flow, excessive synthesis of acetylcholinesterase (AChE), and decreased expression of low-density lipoprotein receptor-related protein-1 (LRP1) as potential targets for Alzheimer's disease treatment. The text suggests that targeting these pathways may help reduce the symptoms of Alzheimer's disease and prevent amyloid accumulation in the brain. However, Jens2013 pages 9-9 does not provide specific information on other potential targets.",
    "sources": [
      {
        "key": "Jens2013 pages 1-1",
        "text": "Jens Moreth, Chrystelle Mavoungou, and K. Schindowski. Passive anti-amyloid immunotherapy in alzheimer's disease: what are the most promising targets? Immunity & Ageing : I & A, 10:18 - 18, 2013."
      },
      {
        "key": "Hampel5481 pages 22-23",
        "text": "H. Hampel, J. Hardy, Kaj Blennow, Christopher Chen, George Perry, S. H. Kim, V. Villemagne, P. Aisen, M. Vendruscolo, T. Iwatsubo, C. Masters, M. Cho, L. Lannfelt, J. L. Cummings, and A. Vergallo. The amyloid-\u03b2 pathway in alzheimer\u2019s disease. Molecular Psychiatry, 26:5481 - 5503, 2021."
      },
      {
        "key": "Chandra5424 pages 17-17",
        "text": "A. Chandra, Polytimi-Eleni Valkimadi, G. Pagano, O. Cousins, G. Dervenoulas, and M. Politis. Applications of amyloid, tau, and neuroinflammation pet imaging to alzheimer's disease and mild cognitive impairment. Human Brain Mapping, 40:5424 - 5442, 2019."
      },
      {
        "key": "Chen2022 pages 4-5",
        "text": "Chen Ma, Fenfang Hong, and Shulong Yang. Amyloidosis in alzheimer\u2019s disease: pathogeny, etiology, and related therapeutic directions. Molecules, 2022."
      },
      {
        "key": "Jens2013 pages 9-9",
        "text": "Jens Moreth, Chrystelle Mavoungou, and K. Schindowski. Passive anti-amyloid immunotherapy in alzheimer's disease: what are the most promising targets? Immunity & Ageing : I & A, 10:18 - 18, 2013."
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "paperqa-1.1.1",
    "date": "2023-04-11",
    "answer": "The text proposes a universal model-agnostic approach that can explain any black-box model prediction in chemistry (Geemi3697 pages 1-1). This approach includes the use of counterfactuals as a category of explanations that provide a rationale behind a model prediction with satisfying properties like providing chemical structure insights. The authors demonstrate the effectiveness of this approach on random forest models, sequence models, and graph neural networks in both classification and regression tasks (Geemi3697 pages 1-1). Additionally, the text mentions Miller's proposed nomenclature within XAI that distinguishes between a prediction explanation, interpretability of a model, and prediction justification (Geemi3697 pages 1-1).",
    "sources": [
      {
        "key": "Geemi3697 pages 1-1",
        "text": "Geemi P. Wellawatte, Aditi Seshadri, and A. White. Model agnostic generation of counterfactual explanations for molecules. Chemical Science, 13:3697 - 3705, 2021."
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "paperqa-1.1.1",
    "date": "2023-04-11",
    "answer": "Birds flock for a variety of reasons, including social, navigational, and anti-predator implications (Usherwood2011). Flying in a flock can result in aerodynamic benefits, reducing power requirements, as demonstrated by a reduction in heart rate and wingbeat frequency in pelicans flying in a V-formation (Usherwood2011). However, the aerodynamic consequences of flying in the more usual \u2018cluster\u2019 flock are not well understood (Usherwood2011). The main goal of the interaction among birds in a flock is to maintain cohesion of the aggregation, which is a strong biological requirement shaped by the evolutionary pressure for survival (Ballerini1232). Stragglers and small groups are significantly more prone to predation than animals belonging to large and highly cohesive aggregations (Ballerini1232). The vast majority of models, both developed by physicists and biologists, adopt a definition of \u2018distance\u2019 that is the same as in physics, i.e. metric distance, and animals can estimate metric distance in various ways, including stereovision, retinal image size, and optic flow (Ballerini1232). The variability of shape in bird flocks increases when there are larger local differences in movement behavior in the flock, which happens when flock size is larger, interacting partners are fewer, the flock turnings are stronger, and individuals roll into the turn (Hemelrijk2011). A major benefit of bird flocking behavior is that it increases collective vigilance and allows for early detection of attacking predators, which relies on rapid transfer of information about danger from the individual first detecting the predator (Mae4173). Acoustic signals or cues of danger are likely to be particularly effective, as information is passed rapidly to all nearby members of a group, and can be detected even if a bird is not currently vigilant or is out of sight (Mae4173). Flocks self-organize to the maximum density at which a typical individual is still just able to see out of the flock in many directions, which provides for faster information transfer and hence rapid flock dynamics, an advantage over local models (Pearce1042). It optimizes the information available to each bird while maintaining the protection of a dense, coherent flock (Pearce1042).",
    "sources": [
      {
        "key": "Usherwood2011 pages 1-1",
        "text": "J. Usherwood, Marinos Stavrou, J. Lowe, K. Roskilly, and Alan M. Wilson. Flying in a flock comes at a cost in pigeons. Nature, 474:494 - 497, 2011."
      },
      {
        "key": "Ballerini1232 pages 2-3",
        "text": "M. Ballerini, N. Cabibbo, R. Candelier, A. Cavagna, E. Cisbani, I. Giardina, V. Lecomte, A. Orlandi, G. Parisi, A. Procaccini, M. Viale, and V. Zdravkovic. Interaction ruling animal collective behavior depends on topological rather than metric distance: evidence from a field study. Proceedings of the National Academy of Sciences, 105:1232 - 1237, 2007."
      },
      {
        "key": "Hemelrijk2011 pages 1-1",
        "text": "C. Hemelrijk and H. Hildenbrandt. Some causes of the variable shape of flocks of birds. PLoS ONE, 2011."
      },
      {
        "key": "Mae4173 pages 1-1",
        "text": "Mae Hingee and R. Magrath. Flights of fear: a mechanical wing whistle sounds the alarm in a flocking bird. Proceedings of the Royal Society B: Biological Sciences, 276:4173 - 4179, 2009."
      },
      {
        "key": "Pearce1042 pages 1-1",
        "text": "D. Pearce, A. M. Miller, G. Rowlands, and M. S. Turner. Role of projection in the control of bird flocks. Proceedings of the National Academy of Sciences, 111:10422 - 10426, 2014."
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "The paper by Geemi et al. (2021) discusses several model-agnostic approaches for explaining predictions from black box models in chemistry, including identifying which features contribute the most, identifying which training data contributes the most, fitting a locally interpretable model around the prediction, and providing contrastive or counterfactual points. The paper also mentions feature importance analysis and local interpretable model-agnostic explanations (LIME), which provide per-feature weights that identify how each feature contributed to the final prediction. Geemi et al. (2021) also introduce a model-agnostic visualization tool named CIME for XAI based on feature attribution, which uses SHAP values and Class Attribution Maps (CAM) to compute feature/atomic attributions. Additionally, the paper discusses a model-agnostic method called MMACE for generating counterfactual explanations for molecules. However, the paper does not mention any other methods for explaining predictions from black box models in chemistry. Philip (2016) also discusses the top-ranked features for auditing black-box models on various datasets, including the Dark Reactions data in chemistry. The top-ranked features for the three models include the minimum Pauling electronegativity and the maximum Pearson electronegativity in the top-ranked cluster of features. The SVM and FNN top features include atomic properties of the inorganics that are related to the electronegativity of an element, so these proxies are correctly also highly ranked. The top-ranked decision tree features additionally include the average molecular polarizability for the organic components, which was previously hypothesized.",
    "sources": [
      {
        "key": "Geemi3697 pages 1-2",
        "text": "Geemi P Wellawatte, Aditi Seshadri, and A. White. Model agnostic generation of counterfactual explanations for molecules. Chemical Science, 13:3697 - 3705, 2021."
      },
      {
        "key": "Geemi3697 pages 4-5",
        "text": "Geemi P Wellawatte, Aditi Seshadri, and A. White. Model agnostic generation of counterfactual explanations for molecules. Chemical Science, 13:3697 - 3705, 2021."
      },
      {
        "key": "Geemi3697 pages 8-9",
        "text": "Geemi P Wellawatte, Aditi Seshadri, and A. White. Model agnostic generation of counterfactual explanations for molecules. Chemical Science, 13:3697 - 3705, 2021."
      },
      {
        "key": "Philip2016 pages 5-6",
        "text": "Philip Adler, Casey Falk, Sorelle A. Friedler, Tionney Nix, Gabriel Rybeck, C. Scheidegger, Brandon Smith, and Suresh Venkatasubramanian. Auditing black-box models for indirect influence. Knowledge and Information Systems, 54:95-122, 2016."
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "The provided sources do not directly state the reasons why birds flock. However, they do provide insights into the collective behavior of bird flocks. Nagy et al. (2010) found that there is a well-defined hierarchy among flock members based on their leading roles in pairwise interactions, and that the average spatial position of a pigeon within the flock strongly correlates with its place in the hierarchy. Cavagna et al. (2010) provided experimental evidence that bird flocks exhibit scale-free correlations, which means that the group cannot be divided into independent sub-parts, and the effective perception range of each individual is as large as the entire group. Attanasi et al. (2014) suggested that the adaptive drive for the high degree of order observed in many living groups may be to achieve a fast and robust collective decision. Ballerini et al. (2008) argued that topological interaction, rather than metric interaction, is the only mechanism that can grant robust cohesion and higher biological fitness. Bialek et al. (2012) found that interactions among neighboring birds in a flock cause an alignment of their flight directions, and the entire flock spontaneously chooses a unique direction in which to fly.",
    "sources": [
      {
        "key": "Nagy2010 pages 1-1",
        "text": "M. Nagy, Zsuzsa \u00c1kos, D. Biro, and T. Vicsek. Hierarchical group dynamics in pigeon flocks. Nature, 464:890-893, 2010."
      },
      {
        "key": "Cavagna1186 pages 3-4",
        "text": "A. Cavagna, A. Cimarelli, I. Giardina, G. Parisi, Raffaele Santagati, F. Stefanini, and M. Viale. Scale-free correlations in starling flocks. Proceedings of the National Academy of Sciences, 107:11865 - 11870, 2009."
      },
      {
        "key": "Attanasi2014 pages 7-8",
        "text": "A. Attanasi, A. Cavagna, L. Del Castello, I. Giardina, T. Grigera, A. Jelic, S. Melillo, L. Parisi, O. Pohl, E. Shen, and M. Viale. Information transfer and behavioural inertia in starling flocks. Nature physics, 10:615 - 698, 2014."
      },
      {
        "key": "Ballerini1232 pages 6-7",
        "text": "M. Ballerini, N. Cabibbo, R. Candelier, A. Cavagna, E. Cisbani, I. Giardina, V. Lecomte, A. Orlandi, G. Parisi, A. Procaccini, M. Viale, and V. Zdravkovic. Interaction ruling animal collective behavior depends on topological rather than metric distance: evidence from a field study. Proceedings of the National Academy of Sciences, 105:1232 - 1237, 2007."
      },
      {
        "key": "Bialek4786 pages 1-1",
        "text": "W. Bialek, A. Cavagna, I. Giardina, T. Mora, Edmondo Silvestri, M. Viale, and A. Walczak. Statistical mechanics for natural flocks of birds. Proceedings of the National Academy of Sciences, 109:4786 - 4791, 2011."
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "There are several potential targets for Alzheimer's disease treatment beyond ABeta. Abyadeh1964 suggests that CRMP2 hyperphosphorylation, the Wnt/beta-catenin pathway, and PPAR alpha and gamma agonists are potential targets. Pioglitazone, a PPAR gamma agonist, has shown promise in clinical trials. Hampel5481 discusses various enzymes and proteins that have potential as therapeutic targets, including the secretases, gamma-secretase heterogeneity in the Aph1 subunit, Presenilin-1, ADAM10, and the secreted amyloid precursor protein ectodomain APPs alpha. Bronzuoli2016 suggests reducing neuroinflammation and inhibiting reactive gliosis as potential targets, with specific examples of potential treatments including minocycline, sirtuin modulators, B2 receptor blockers, glaucocalyxin B, palmitoylethanolamide, and S100B inhibitors. However, there is no consensus on which targets are most promising for Alzheimer's disease treatment. (Abyadeh1964 pages 13-13, Abyadeh1964 pages 2-3, Hampel5481 pages 17-17, Bronzuoli2016 pages 9-10)",
    "sources": [
      {
        "key": "Jens2013 pages 1-1",
        "text": "Jens Moreth, Chrystelle Mavoungou, and K. Schindowski. Passive anti-amyloid immunotherapy in alzheimer's disease: what are the most promising targets? Immunity & Ageing : I & A, 10:18 - 18, 2013."
      },
      {
        "key": "Abyadeh1964 pages 13-13",
        "text": "M. Abyadeh, Vivek Gupta, Veer Bala Gupta, Nitin Chitranshi, Yunqi Wu, A. Amirkhani, A. Meyfour, Samran Sheriff, Ting Shen, Kunal Dhiman, G. Salekdeh, P. Haynes, S. Graham, and M. Mirzaei. Comparative analysis of aducanumab, zagotenemab and pioglitazone as targeted treatment strategies for alzheimer\u2019s disease. Aging and Disease, 12:1964 - 1976, 2021."
      },
      {
        "key": "Abyadeh1964 pages 2-3",
        "text": "M. Abyadeh, Vivek Gupta, Veer Bala Gupta, Nitin Chitranshi, Yunqi Wu, A. Amirkhani, A. Meyfour, Samran Sheriff, Ting Shen, Kunal Dhiman, G. Salekdeh, P. Haynes, S. Graham, and M. Mirzaei. Comparative analysis of aducanumab, zagotenemab and pioglitazone as targeted treatment strategies for alzheimer\u2019s disease. Aging and Disease, 12:1964 - 1976, 2021."
      },
      {
        "key": "Hampel5481 pages 17-17",
        "text": "H. Hampel, J. Hardy, Kaj Blennow, Christopher Chen, George Perry, S. H. Kim, V. Villemagne, P. Aisen, M. Vendruscolo, T. Iwatsubo, C. Masters, M. Cho, L. Lannfelt, J. L. Cummings, and A. Vergallo. The amyloid-\u03b2 pathway in alzheimer\u2019s disease. Molecular Psychiatry, 26:5481 - 5503, 2021."
      },
      {
        "key": "Bronzuoli2016 pages 9-10",
        "text": "M. R. Bronzuoli, A. Iacomino, L. Steardo, and C. Scuderi. Targeting neuroinflammation in alzheimer\u2019s disease. Journal of Inflammation Research, 9:199 - 208, 2016."
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "The choice between SELFIEs and SMILES as a representation of molecules for deep learning depends on the specific application and available resources (Akshat7079 pages 12-12). While SELFIEs are more expressive and can represent a larger chemical space than SMILES (Akshat7079 pages 12-12), they are also more computationally expensive and require more memory (Akshat7079 pages 12-12). SELFIEs allow for efficient algorithms to perform exploration and interpolation in the chemical space without the need for extensive training times, large datasets, and hand-crafted rules for obtaining novel molecules (Akshat7079 pages 1-2). However, the text does not provide a direct comparison of the advantages and disadvantages of using SELFIEs and SMILES representations for deep learning in molecular modeling (Akshat7079 pages 4-4, 8-9). Therefore, it is difficult to determine which representation is better for deep learning without further research.",
    "sources": [
      {
        "key": "Akshat7079 pages 5-6",
        "text": "AkshatKumar Nigam, R. Pollice, M. Krenn, Gabriel dos Passos Gomes, and Al\u00e1n Aspuru-Guzik. Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (stoned) algorithm for molecules using selfies\u2020. Chemical Science, 12:7079 - 7090, 2020."
      },
      {
        "key": "Akshat7079 pages 1-2",
        "text": "AkshatKumar Nigam, R. Pollice, M. Krenn, Gabriel dos Passos Gomes, and Al\u00e1n Aspuru-Guzik. Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (stoned) algorithm for molecules using selfies\u2020. Chemical Science, 12:7079 - 7090, 2020."
      },
      {
        "key": "Akshat7079 pages 12-12",
        "text": "AkshatKumar Nigam, R. Pollice, M. Krenn, Gabriel dos Passos Gomes, and Al\u00e1n Aspuru-Guzik. Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (stoned) algorithm for molecules using selfies\u2020. Chemical Science, 12:7079 - 7090, 2020."
      },
      {
        "key": "Akshat7079 pages 4-4",
        "text": "AkshatKumar Nigam, R. Pollice, M. Krenn, Gabriel dos Passos Gomes, and Al\u00e1n Aspuru-Guzik. Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (stoned) algorithm for molecules using selfies\u2020. Chemical Science, 12:7079 - 7090, 2020."
      },
      {
        "key": "Akshat7079 pages 8-9",
        "text": "AkshatKumar Nigam, R. Pollice, M. Krenn, Gabriel dos Passos Gomes, and Al\u00e1n Aspuru-Guzik. Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (stoned) algorithm for molecules using selfies\u2020. Chemical Science, 12:7079 - 7090, 2020."
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "Salamanders have evolved diverse respiratory systems for acquiring oxygen from the environment, including skin, gills, and lungs that may coexist within the same species (Hsia2013 pages 1-1). Cutaneous gas exchange is enhanced by erythrocyte fragmentation in salamanders that possess large erythrocytes (Hsia2013 pages 35-36). The text does not provide specific information about whether salamanders use their skin, lungs, or other structures for breathing (Hsia2013 pages 34-35). However, in lung-breathing tetrapods, the respiratory apparatus consists of a gas-exchanger intimately connected to a passive pump, an active pump containing the respiratory musculature, and a central nervous control element that coordinates pump activity and optimizes the function of the gas exchanger. The gas exchanger communicates with the CNCE mainly via circulation, using blood pH and O2 saturation to regulate the frequency and amplitude of active ventilation. The structure of amniote gas-exchange tissue is superficially similar to that in lungfish or lissamphibians (Hsia2013 pages 35-36).",
    "sources": [
      {
        "key": "Hsia2013 pages 35-36",
        "text": "C. Hsia, A. Schmitz, M. Lambertz, S. Perry, and J. Maina. Evolution of air breathing: oxygen homeostasis and the transitions from water to land and sky. Comprehensive Physiology, 3 2:849-915, 2013."
      },
      {
        "key": "Hsia2013 pages 1-1",
        "text": "C. Hsia, A. Schmitz, M. Lambertz, S. Perry, and J. Maina. Evolution of air breathing: oxygen homeostasis and the transitions from water to land and sky. Comprehensive Physiology, 3 2:849-915, 2013."
      },
      {
        "key": "Hsia2013 pages 34-35",
        "text": "C. Hsia, A. Schmitz, M. Lambertz, S. Perry, and J. Maina. Evolution of air breathing: oxygen homeostasis and the transitions from water to land and sky. Comprehensive Physiology, 3 2:849-915, 2013."
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "Bispecific CD38 antibodies bind to CD38, a transmembrane glycoprotein expressed on the surface of multiple myeloma (MM) cells, and CD3, a T cell receptor. This binding leads to the activation of T cells and the subsequent killing of MM cells (Chiara2020 pages 14-14). Bispecific CD38 antibodies, such as GBR1342, engage T cells to kill myeloma cells (Chiara2020 pages 23-23). Bispecific CAR-T cells that target both CD38 and BCMA are designed to bind to both CD38 and BCMA, leading to the destruction of the cancer cells (Tang2022 pages 15-15). Bispecific CD38 antibodies can also bind to another target, such as CD47, to induce phagocytosis of myeloma cells (Donk2018 pages 9-9). Overall, bispecific CD38 antibodies treat myeloma by recruiting T-cells to target and kill myeloma cells (Xiang2020 pages 11-11).",
    "sources": [
      {
        "key": "Chiara2020 pages 14-14",
        "text": "Chiara Caraccio, Sachi Krishna, D. Phillips, and C. Sch\u00fcrch. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Frontiers in Immunology, 2020."
      },
      {
        "key": "Tang2022 pages 15-15",
        "text": "Y. Tang, Haisen Yin, Xinying Zhao, D. Jin, Yan Liang, Tao Xiong, Lu Li, W. Tang, Jiangzhao Zhang, Min Liu, Zhuojun Yu, Huimin Liu, Sibin Zang, and Zhiping Huang. High efficacy and safety of cd38 and bcma bispecific car-t in relapsed or refractory multiple myeloma. Journal of Experimental & Clinical Cancer Research : CR, 2022."
      },
      {
        "key": "Chiara2020 pages 23-23",
        "text": "Chiara Caraccio, Sachi Krishna, D. Phillips, and C. Sch\u00fcrch. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Frontiers in Immunology, 2020."
      },
      {
        "key": "Donk2018 pages 9-9",
        "text": "N. V. D. van de Donk and S. Usmani. Cd38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Frontiers in Immunology, 2018."
      },
      {
        "key": "Xiang2020 pages 11-11",
        "text": "Xiang Zhou, H. Einsele, and S. Danhof. Bispecific antibodies: a new era of treatment for multiple myeloma. Journal of Clinical Medicine, 2020."
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "Insufficient information is provided in the sources to answer this question directly. While the sources discuss the use of microorganisms, specifically cyanobacteria, for the synthesis of biodegradable plastics, they do not provide specific information on the materials and energy required for microorganisms to synthesize plastics. However, the sources do mention the potential of using renewable raw materials and atmospheric CO2 as sources of carbon for the production of bioplastics, as well as the use of organic substrates and energy-intensive procedures for fermentation and PHA extraction. Genetic engineering is also mentioned as a technique to improve the production of biopolymers in microorganisms. Further research is needed to determine the specific materials and energy requirements for microorganisms to synthesize plastics.",
    "sources": [
      {
        "key": "Urbanek7669 pages 8-8",
        "text": "A. Urbanek, W. Rymowicz, and A. Miro\u0144czuk. Degradation of plastics and plastic-degrading bacteria in cold marine habitats. Applied Microbiology and Biotechnology, 102:7669 - 7678, 2018."
      },
      {
        "key": "Preeti2022 pages 4-4",
        "text": "Preeti Agarwal, R. Soni, Pritam Kaur, Akanksha Madan, Reema Mishra, Jayati Pandey, Shreya Singh, and Garvita Singh. Cyanobacteria as a promising alternative for sustainable environment: synthesis of biofuel and biodegradable plastics. Frontiers in Microbiology, 2022."
      },
      {
        "key": "Preeti2022 pages 2-2",
        "text": "Preeti Agarwal, R. Soni, Pritam Kaur, Akanksha Madan, Reema Mishra, Jayati Pandey, Shreya Singh, and Garvita Singh. Cyanobacteria as a promising alternative for sustainable environment: synthesis of biofuel and biodegradable plastics. Frontiers in Microbiology, 2022."
      },
      {
        "key": "Preeti2022 pages 14-15",
        "text": "Preeti Agarwal, R. Soni, Pritam Kaur, Akanksha Madan, Reema Mishra, Jayati Pandey, Shreya Singh, and Garvita Singh. Cyanobacteria as a promising alternative for sustainable environment: synthesis of biofuel and biodegradable plastics. Frontiers in Microbiology, 2022."
      },
      {
        "key": "Preeti2022 pages 23-23",
        "text": "Preeti Agarwal, R. Soni, Pritam Kaur, Akanksha Madan, Reema Mishra, Jayati Pandey, Shreya Singh, and Garvita Singh. Cyanobacteria as a promising alternative for sustainable environment: synthesis of biofuel and biodegradable plastics. Frontiers in Microbiology, 2022."
      },
      {
        "key": "Preeti2022 pages 21-22",
        "text": "Preeti Agarwal, R. Soni, Pritam Kaur, Akanksha Madan, Reema Mishra, Jayati Pandey, Shreya Singh, and Garvita Singh. Cyanobacteria as a promising alternative for sustainable environment: synthesis of biofuel and biodegradable plastics. Frontiers in Microbiology, 2022."
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "Carbon nanotubes can be manufactured at scale using the Langmuir-Blodgett (LB) method, which achieves monolayers of aligned non-covalently functionalized single-walled carbon nanotubes (SWNTs) from organic solvent with dense packing. The monolayer SWNTs can be patterned for device integration by microfabrication, enabling the high currents (~3mA) SWNT devices with narrow channel widths. The method is generic for different bulk materials with various diameters (Xiaoling4890 pages 1-1). Another method for producing graphene nanoribbons (GNRs) is by unzipping the side walls of multi-walled carbon nanotubes (MWCNTs) using intercalation with suitable ions. The intertube intercalation of CNTs by different ions has been shown to be an effective method to decrease the van der Waals interactions between individual tubes and assist the exfoliation of bundled CNTs. By selecting appropriate neutral molecules or ions to substitute H2SO4 as an intercalation agent, it shall be a promising approach to produce GNRs with a high yield and further reduce the usage of strong acid during the nanotube unzipping (Yan2016 pages 1-2). Additionally, a green and scalable method for the synthesis of graphene nanoribbons is by intercalation-assisted longitudinal unzipping of multi-walled carbon nanotubes (MWCNTs) with KNO3 and H2SO4, which decreases the strong van der Waals attractions in the MWCNTs bundles and between the coaxial graphene walls of CNTs. The developed methodology possesses the ability to synthesize GNRs effectively with an improved CNT concentration in H2SO4 of 10 mg/ml at 70 \u00b0C, which is amenable to industrial-scale production because of the decreased amount of strong acid (Yan2016 pages 1-1). The LB assembly of densely aligned SWNTs can be combined with chemical separation and selective chemical reaction methods to afford purely metallic or semiconducting SWNTs in massive parallel configuration useful for interconnection or high-speed transistor applications at large scale (Xiaoling4890 pages 2-2).",
    "sources": [
      {
        "key": "Xiaoling4890 pages 1-1",
        "text": "Xiaoling Li, Li Zhang, Xinran Wang, I. Shimoyama, Xiaoming Sun, W. Seo, and H. Dai. Langmuir-blodgett assembly of densely aligned single-walled carbon nanotubes from bulk materials. Journal of the American Chemical Society, 129 16:4890-1, 2007."
      },
      {
        "key": "Yan2016 pages 1-2",
        "text": "Yan-sheng Li, Jia-Liang Liao, Shan-Yu Wang, and Wei\u2010Hung Chiang. Intercalation-assisted longitudinal unzipping of carbon nanotubes for green and scalable synthesis of graphene nanoribbons. Scientific Reports, 2016."
      },
      {
        "key": "Yan2016 pages 1-1",
        "text": "Yan-sheng Li, Jia-Liang Liao, Shan-Yu Wang, and Wei\u2010Hung Chiang. Intercalation-assisted longitudinal unzipping of carbon nanotubes for green and scalable synthesis of graphene nanoribbons. Scientific Reports, 2016."
      },
      {
        "key": "Yan2016 pages 11-11",
        "text": "Yan-sheng Li, Jia-Liang Liao, Shan-Yu Wang, and Wei\u2010Hung Chiang. Intercalation-assisted longitudinal unzipping of carbon nanotubes for green and scalable synthesis of graphene nanoribbons. Scientific Reports, 2016."
      },
      {
        "key": "Xiaoling4890 pages 2-2",
        "text": "Xiaoling Li, Li Zhang, Xinran Wang, I. Shimoyama, Xiaoming Sun, W. Seo, and H. Dai. Langmuir-blodgett assembly of densely aligned single-walled carbon nanotubes from bulk materials. Journal of the American Chemical Society, 129 16:4890-1, 2007."
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "As of 2022, only symptomatic treatments are available for ALS, and disease-modifying therapies have been elusive despite over 70 randomized trials of putative new therapeutic agents over the past two decades (Roberts2022 pages 14-15). Pain management, therapeutic exercise, and physiotherapy are recommended to alleviate pain and slow symptomatic progression (Roberts2022 pages 9-10). Riluzole and edaravone are the only two drugs approved by the FDA for ALS treatment, with riluzole being the most widely used, but their efficacy remains controversial (Roberts2022 pages 9-10). Antisense therapeutics targeting synucleinopathy in ALS are being researched as a potential avenue for treatment (Roberts2022 pages 9-10). Two RNA-based therapeutics, jacifusen for FUS and tofersen for SOD1, are being researched for ALS as of 2022, with tofersen currently in a phase III trial showing signs of slowing disease progression in patients with SOD1-ALS (Anja2022 pages 8-8). However, further research is required to provide a clearer understanding of synucleinopathy development in various ALS patient groups, at different stages of the disease process, as well as further investigation of the interactions between Syn and other ALS-associated proteins across the spectrum of neurodegenerative diseases (Roberts2022 pages 14-15). Additionally, various potential therapeutic targets for ALS are being researched, including astrocytes, neuronal cholesterol synthesis, oligodendroglial myelination, NAD+ precursors and antioxidants, SIRT3 activation, and gut microbiome and metabolites (Agrawal2022 pages 27-27).",
    "sources": [
      {
        "key": "Roberts2022 pages 14-15",
        "text": "B. Roberts, F. Theunissen, F. Mastaglia, P. Akkari, and L. L. Flynn. Synucleinopathy in amyotrophic lateral sclerosis: a potential avenue for antisense therapeutics? International Journal of Molecular Sciences, 2022."
      },
      {
        "key": "Roberts2022 pages 9-10",
        "text": "B. Roberts, F. Theunissen, F. Mastaglia, P. Akkari, and L. L. Flynn. Synucleinopathy in amyotrophic lateral sclerosis: a potential avenue for antisense therapeutics? International Journal of Molecular Sciences, 2022."
      },
      {
        "key": "Anja2022 pages 1-1",
        "text": "Anja Holm, Stine N Hansen, H. Klitgaard, and S. Kauppinen. Clinical advances of rna therapeutics for treatment of neurological and neuromuscular diseases. RNA Biology, 19:594 - 608, 2022."
      },
      {
        "key": "Anja2022 pages 8-8",
        "text": "Anja Holm, Stine N Hansen, H. Klitgaard, and S. Kauppinen. Clinical advances of rna therapeutics for treatment of neurological and neuromuscular diseases. RNA Biology, 19:594 - 608, 2022."
      },
      {
        "key": "Agrawal2022 pages 27-27",
        "text": "I. Agrawal, Yong Shan Lim, Shi\u2010Yan Ng, and Shuo-Chien Ling. Deciphering lipid dysregulation in als: from mechanisms to translational medicine. Translational Neurodegeneration, 2022."
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-26",
    "answer": "I cannot answer",
    "sources": []
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "paperqa-1.2.0",
    "date": "2023-04-27",
    "answer": "There are several clustering techniques available for analyzing protein structures output from a molecular dynamics trajectory. One approach is to use principal component (PC) analysis and subsequent clustering techniques, such as K-means and average-linkage algorithms, to group similar structures into subgroups based on their conformational changes (Antje2012 pages 1-1, Antje2012 pages 3-3). Another approach is to use CAVER 3.0, which implements new algorithms for both the calculation and clustering of pathways. The algorithm consists of three separable steps: identification of pathways in each provided structure, clustering of pathways identified in all snapshots, and calculation and generation of output data. The implemented hierarchical average-link clustering algorithm ensures robust clustering results and enables an easy adjustment of the clustering parameters (Chovancov2012 pages 2-2). Additionally, machine learning techniques, such as k-nearest neighbor classifiers, can be used to classify large datasets of protein structures based on their identified pathway clusters (Chovancov2012 pages 4-5). However, the appropriate clustering algorithm and interpretation of results can be complex and require careful consideration (Antje2012 pages 1-1).",
    "sources": [
      {
        "key": "Chovancov2012 pages 2-2",
        "text": "E. Chovancov\u00e1, A. Pavelka, P. Benes, Ondrej Strnad, J. Brezovsky, B. Kozl\u00edkov\u00e1, Artur G\u00f3ra, Vil\u00e9m Sustr, M. Klva\u0148a, Petr Medek, L. Biedermannov\u00e1, Jir\u00ed Sochor, and J. Damborsk\u00fd. Caver 3.0: a tool for the analysis of transport pathways in dynamic protein structures. PLoS Computational Biology, 2012."
      },
      {
        "key": "Antje2012 pages 1-1",
        "text": "Antje Wolf and K. Kirschner. Principal component and clustering analysis on molecular dynamics data of the ribosomal l11\u00b723s subdomain. Journal of Molecular Modeling, 19:539 - 549, 2012."
      },
      {
        "key": "Chovancov2012 pages 4-5",
        "text": "E. Chovancov\u00e1, A. Pavelka, P. Benes, Ondrej Strnad, J. Brezovsky, B. Kozl\u00edkov\u00e1, Artur G\u00f3ra, Vil\u00e9m Sustr, M. Klva\u0148a, Petr Medek, L. Biedermannov\u00e1, Jir\u00ed Sochor, and J. Damborsk\u00fd. Caver 3.0: a tool for the analysis of transport pathways in dynamic protein structures. PLoS Computational Biology, 2012."
      },
      {
        "key": "Antje2012 pages 3-3",
        "text": "Antje Wolf and K. Kirschner. Principal component and clustering analysis on molecular dynamics data of the ribosomal l11\u00b723s subdomain. Journal of Molecular Modeling, 19:539 - 549, 2012."
      },
      {
        "key": "Roe3084 pages 12-12",
        "text": "D. Roe and T. Cheatham. Ptraj and cpptraj: software for processing and analysis of molecular dynamics trajectory data. Journal of chemical theory and computation, 9 7:3084-95, 2013."
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "perplexity",
    "date": "2023-04-07",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods. One method is chemical vapor deposition (CVD), which utilizes high energy to atomize gaseous carbon sources such as methane, carbon monoxide, and acetylene[1]. Another method is laser ablation, which uses a high-power laser to vaporize a graphite source loaded with a metal catalyst[2]. Researchers at Western Michigan University\n have also developed a method for forming carbon nanotubes in a \nhigh-density, closely packed configuration, enabling their large-scale \nproduction[3]. Recently, MIT\n researchers have demonstrated that carbon nanotube transistors can be \nmade swiftly in commercial facilities, with the same equipment used to \nmanufacture silicon-based transistors[4].",
    "sources": [
      {
        "key": "1",
        "text": "https://www.britannica.com/science/carbon-nanotube"
      },
      {
        "key": "2",
        "text": "https://www.azonano.com/article.aspx?ArticleID=1108"
      },
      {
        "key": "3",
        "text": "https://wmich.edu/research/large-scale"
      },
      {
        "key": "4",
        "text": "https://news.mit.edu/2020/carbon-nanotube-transistors-factory-0601"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "perplexity",
    "date": "2023-04-07",
    "answer": "Bispecific CD38\n antibodies are designed to bind to both CD38, a protein found on the \nsurface of multiple myeloma (MM) cells, and CD3, a protein found on T \ncells[1][2]. By binding to both CD38 and CD3, bispecific CD38 antibodies activate T cells to attack and kill MM cells[1][3]. This mechanism of action is similar to that of other anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab[4].\n Bispecific CD38 antibodies are a novel immunotherapeutic modality that \nhas shown impressive preliminary efficacy in heavily treated MM patients[1]. They are expected to become an integral part of the MM treatment paradigm in the near future[1].",
    "sources": [
      {
        "key": "1",
        "text": "https://aacrjournals.org/bloodcancerdiscov/article/2/5/423/665839/Bispecific-Antibodies-in-Multiple-Myeloma-Present"
      },
      {
        "key": "2",
        "text": "https://www.news-medical.net/whitepaper/20210817/Targeting-CD38CD3-in-the-immunotherapy-of-multiple-myeloma.aspx"
      },
      {
        "key": "3",
        "text": "https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1814253"
      },
      {
        "key": "4",
        "text": "https://ashpublications.org/blood/article/138/Supplement%201/1580/480536/The-Role-of-CD38-in-Multiple-Myeloma-Cell-Biology"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "scite",
    "date": "2023-04-09",
    "answer": "As of 2022, there are limited treatment options available for amyotrophic lateral sclerosis (ALS) patients [1]. The only two modestly efficacious disease-modifying drugs available are riluzole and edaravone [1][6]. However, there are several therapeutics being researched for ALS treatment. Cell-based therapy has been proposed as an ultimate source for regeneration of motor neurons (MNs) [2][4]. Recent completion of non-autologous fetal spinal stem cell transplant to ALS patients brought renewed hope for further human trials to cure the disease [2]. Autologous somatic stem cell-based human trials are now in track to reveal the outcome of the ongoing trials [2]. Furthermore, induced pluripotent stem cell (iPSC)-based ALS disease drug screen and autologous cell transplant options will broaden therapeutic options [2]. Astrocyte-based cell therapy is another potential treatment for ALS [3]. Embryonic stem cell-derived astrocytes behave as highly trophic \u201cyoung astrocytes\u201d, being able to delay disease onset and prolong survival when injected intrathecally in murine models of ALS overexpressing the SOD1G93A mutation [3]. The safety and therapeutic potential of these cells are currently being evaluated in a clinical trial in ALS patients [3]. Human umbilical cord blood (hUCB) cells may be a promising new treatment for ALS, mainly by providing a protective microenvironment for motor neuron survival [5]. Among multiple advantages, hUCB cells' production of various anti-inflammatory/growth/trophic factors makes them an attractive cell source for ALS therapy [5]. Biodistribution and optimal hUCB cell dose for transplantation have been determined in current ALS clinical trials [5]. In addition to cell-based therapy, positron emission tomography (PET) imaging has promise as a biomarker for ALS because it permits visualization of central nervous system (CNS) pathology in individuals living with ALS [1]. PET radioligands that target a variety of potential pathophysiological mechanisms\u2014including cerebral metabolism, neuroinflammation, neuronal dysfunction, and oxidative stress\u2014has enabled dynamic interrogation of molecular changes in ALS, in both natural history studies and human clinical trials [1]. In conclusion, while there are limited treatment options available for ALS patients, there are several promising therapeutics being researched, including cell-based therapy, astrocyte-based cell therapy, and human umbilical cord blood cells. PET imaging also has potential as a diagnostic biomarker for ALS.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.frontiersin.org/articles/10.3389/fneur.2019.00135/full"
      },
      {
        "key": "2",
        "text": "https://www.en-journal.org/journal/view.html?doi=10.5607/en.2014.23.3.207"
      },
      {
        "key": "3",
        "text": "https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-1006-y"
      },
      {
        "key": "4",
        "text": "10.4172/2325-9620.1000118"
      },
      {
        "key": "5",
        "text": "https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1323862"
      },
      {
        "key": "6",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/med.21528"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "perplexity",
    "date": "2023-04-09",
    "answer": "As of 2022, there are six FDA-approved drugs for treating ALS and its symptoms, including RELYVRIO, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta[1]. There are also several therapies being researched for ALS treatment. For example, an experimental drug is being tested in a global phase 3 clinical trial based on promising results from a study at Columbia University[2]. Tofersen is another therapy being investigated for treating ALS caused by mutations in the SOD1 gene[3]. Additionally, NU-9 is a potential ALS treatment that has shown to be more effective than existing FDA-approved drugs when given in combination with riluzole and edaravone[4]. The ALS Association is currently funding 121 active research projects in 12 countries with $44 million committed to research[5].",
    "sources": [
      {
        "key": "1",
        "text": "https://www.als.org/navigating-als/living-with-als/fda-approved-drugs"
      },
      {
        "key": "2",
        "text": "https://www.cuimc.columbia.edu/news/promising-als-therapy-moves-closer-clinic"
      },
      {
        "key": "3",
        "text": "https://www.ajmc.com/view/overview-of-current-and-emerging-therapies-for-amyotrophic-lateral-sclerosis"
      },
      {
        "key": "4",
        "text": "https://news.northwestern.edu/stories/2022/05/new-als-drug-is-more-effective-than-existing-ones/"
      },
      {
        "key": "5",
        "text": "https://www.als.org/2022-year-review"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "There are several ways to cluster protein structures output from a molecular dynamics trajectory. One common method is cluster analysis, which involves grouping similar conformations together[1]. Clustering algorithms have been widely used to reduce the dimensionality of molecular dynamics trajectories[2]. Principal Component Analysis (PCA) is another method that can be used to cluster protein structures[3]. The goal of clustering is to partition data so that data points inside a cluster are more similar to each other than they are to points outside a cluster[1]. Structural features from the substrate-binding cavity of the receptor can also be used to optimize docking experiments on a cloud[2].",
    "sources": [
      {
        "key": "1",
        "text": "https://amberhub.chpc.utah.edu/clustering-a-protein-trajectory/"
      },
      {
        "key": "2",
        "text": "https://pubmed.ncbi.nlm.nih.gov/25873944/"
      },
      {
        "key": "3",
        "text": "https://www.nature.com/articles/s41598-022-13714-z"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "To cluster protein structures output from a molecular dynamics trajectory, several methods can be used. One such method is fuzzy clustering, which can locate classes of similar three-dimensional conformations explored during a molecular dynamics simulation [1]. Another method is quantum clustering, which can objectively cluster the conformations sampled by molecular dynamics simulations performed on different ligand-bound structures of the protein [2]. K-means clustering is another widely used clustering algorithm that can be implemented in the protein essential dynamics subspace defined by principal component analysis on the molecular dynamics trajectory [4]. In addition to clustering, visualizing the solvent paths entering and leaving cavities of the protein can also be useful in studying the route and dynamics of the exchange of tightly bound internal water molecules with the bulk solvent [3]. Overall, the choice of clustering method depends on the specific research question and the type of data being analyzed. It is important to choose a method that is appropriate for the data and can provide meaningful insights into the protein structures.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/prot.340140211"
      },
      {
        "key": "2",
        "text": "https://pubs.rsc.org/en/content/articlelanding/2011/MB/c1mb05038a"
      },
      {
        "key": "3",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/j.1467-8659.2008.01227.x"
      },
      {
        "key": "4",
        "text": "https://www.worldscientific.com/doi/abs/10.1142/S0219633613410083"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, there are several factors to consider. The diene component must be able to assume an s-cis conformation, and electron-withdrawing groups on the dienophile facilitate the reaction. Electron-donating groups on the diene also facilitate the reaction[1]. Controlling the reaction to select for the endo product relies on changing the HOMO and/or LUMO of the system[2]. The reactivity and stereoselectivity in the Lewis acid-catalyzed Diels-Alder reaction are controlled by a combination of several interaction terms[3]. Physical factors leading to the computed periodic reactivity trend upon going from the uncatalyzed to the bond-catalyzed Diels-Alder reactions can be analyzed and compared[4]. Additionally, external electric fields can be used as a catalyst to manipulate the reactivity and selectivity of the reaction[5].",
    "sources": [
      {
        "key": "1",
        "text": "https://chem.libretexts.org/Courses/University_of_Illinois_Springfield/UIS%3A_CHE_269_(Morsch_and_Andrews)/Chapters/Chapter_16%3A_Conjugation%2C_Resonance%2C_and_Dienes/16.11_Rules_of_the_Diels%E2%80%93Alder_Reaction"
      },
      {
        "key": "2",
        "text": "https://chem.libretexts.org/Courses/University_of_California_Davis/UCD_Chem_231A%3A_Methods_of_Organic_Synthesis/Text/Diels-Alder_Reaction"
      },
      {
        "key": "3",
        "text": "https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/open.202000112"
      },
      {
        "key": "4",
        "text": "https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/chem.202100522"
      },
      {
        "key": "5",
        "text": "https://www.nature.com/articles/nature16989/"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, several factors should be considered. The nature of the catalyst can affect the reaction rate, selectivity, and yield of the product. The following are some factors to consider when selecting a catalyst for a Diels-Alder reaction: 1. Lewis acidity: Catalysts with high Lewis acidity can activate the dienophile and diene, leading to faster reaction rates and higher yields. For example, silica and alumina modified by Lewis acids have been shown to be efficient catalysts in Diels-Alder reactions of carbonyl-containing dienophiles [2]. 2. Chirality: Chiral catalysts can induce enantioselectivity in the reaction, leading to the formation of a single enantiomer of the product. For example, oxazaborolidinone-catalyzed enantioselective Diels-Alder reactions have been reported [1]. 3. Stability: Catalysts that are stable under the reaction conditions can be reused, reducing the cost of the reaction. For example, the catalyst SiO2\u00b7AlClEt2 retains a great deal of its catalytic activity when recovered or stored in the open air for one month [2]. 4. Endo/exo selectivity: Catalysts can influence the endo/exo selectivity of the reaction, leading to the formation of either endo or exo adducts. For example, allo-threonine-derived O-acyl-B-phenyl-oxazaborolidinones are highly enantioselective Lewis acid catalysts for the Diels-Alder reaction of simple acyclic enone dienophiles, expanding the scope of ketone dienophiles and dienes [1]. 5. Reactivity: Catalysts can affect the reactivity of the dienophile and diene, leading to the formation of the desired product. For example, carbocations such as Ph3C+ have been shown to be extremely efficient, mild, and selective Lewis acid catalysts for Diels-Alder reactions [3]. In summary, when selecting a catalyst for a Diels-Alder reaction, factors such as Lewis acidity, chirality, stability, endo/exo selectivity, and reactivity should be considered. The choice of catalyst can significantly affect the reaction rate, selectivity, and yield of the product [1]. [2][3]",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.acs.org/doi/10.1021/jo702043g"
      },
      {
        "key": "2",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/chin.199337096"
      },
      {
        "key": "3",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/chin.201427035"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Based on the provided search results, selfies and smiles are both used as molecular representations for deep learning. SMILES is a popular string-based representation that has been used in computational chemistry for decades[1][2]. SELFIES is a newer representation that has been shown to be more diverse and robust than SMILES[3][1][4]. Geometric representations are also becoming more important in molecular deep learning[5]. Therefore, the choice between selfies or smiles as a better representation of molecules for deep learning may depend on the specific application and the type of information that needs to be extracted from the molecular structure.\n",
    "sources": [
      {
        "key": "1",
        "text": "https://arxiv.org/abs/2204.00056"
      },
      {
        "key": "2",
        "text": "https://iopscience.iop.org/article/10.1088/2632-2153/aba947"
      },
      {
        "key": "3",
        "text": "https://arxiv.org/abs/1905.13741"
      },
      {
        "key": "4",
        "text": "https://deepai.org/publication/selfies-and-the-future-of-molecular-string-representations"
      },
      {
        "key": "5",
        "text": "https://www.nature.com/articles/s42256-021-00418-8"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Deep learning has brought a dramatic development in molecular property prediction that is crucial in the field of drug discovery using various representations such as fingerprints, SMILES, and graphs [1]. SMILES is commonly used in chemistry applications with SMILES sequences [2]. However, SMILES has a limitation in that it is hard to reflect chemical properties [1]. SELFIEs, on the other hand, have been shown to be superior to SMILES for tasks such as Optical Chemical Entity Recognition [4][5]. SELFIEs match the representation used in MACCS, which is commonly used in regression models [2]. However, using SELFIEs over SMILES does not necessarily translate to better supervised learning performance [2]. In addition, there exists a performance gap between the existing unpretrained SMILES-based models and graph-based models at large-scale benchmark results, while pretrain models are resource-demanding at training [3]. Therefore, it can be concluded that SELFIEs are a better representation of molecules for deep learning than SMILES, but the choice of representation depends on the specific task and the availability of resources.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/s41598-021-90259-7"
      },
      {
        "key": "2",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/613268f0d5f0803706ba0c79"
      },
      {
        "key": "3",
        "text": "https://arxiv.org/abs/2112.13305"
      },
      {
        "key": "4",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/60c756c2567dfe48eaec654c"
      },
      {
        "key": "5",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/60c75681567dfe722dec64d6"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "There are several promising targets for Alzheimer's disease beyond Abeta. These include:\n\u2022 Lecanemab, a medicine that slows cognitive decline in people with early Alzheimer's disease by 27% [1]\n\u2022 Immune cells, toxic protein tangles, and brain waves[2]\n\u2022 Tau proteins, which are a promising target for passive immunotherapy[3]\n\u2022 APOE4, pericytes, and Cyclophilin A, which have been shown to accelerate blood-brain barrier breakdown and are potential targets for treatment[4]\n\u2022 Immunotherapies based on other targets such as tau, microglia, and the gut-brain axis are also under development[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780"
      },
      {
        "key": "2",
        "text": "https://www.npr.org/sections/health-shots/2021/08/09/1026207499/new-treatments-look-for-ways-to-protect-the-brain-from-alzheimers"
      },
      {
        "key": "3",
        "text": "https://pubmed.ncbi.nlm.nih.gov/32682954/"
      },
      {
        "key": "4",
        "text": "https://www.sciencedaily.com/releases/2021/06/210614131220.htm"
      },
      {
        "key": "5",
        "text": "https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-022-00292-3"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Alzheimer's disease is a multifactorial neurodegenerative disorder with many drug targets contributing to its etiology [3]. While increased production and deposition of amyloid beta-protein (Abeta) are believed to be key pathogenic events in Alzheimer's disease, other potential therapeutic targets have been identified [1][2][4]. Glycogen synthase kinase-3 beta (GSK-3\u03b2) and cyclin-dependent kinase 5 (CDK5) have been identified as being involved in the pathological hyperphosphorylation of tau proteins, which leads to the formation of neurofibrillary tangles and causes Alzheimer's disease [3]. Inhibition of p38 mitogen-activated protein kinase (MAPK) is also considered a promising strategy for the treatment of Alzheimer's disease [4]. Additionally, peripheral blood biomarkers offer a promising, non-intrusive mechanism for early Alzheimer's disease diagnosis [5]. The corpus callosum has also been identified as a novel target for human neural stem cell transplantation in transgenic Alzheimer's disease mouse models [6]. Therefore, potential therapeutic targets for Alzheimer's disease, other than Abeta, include GSK-3\u03b2, CDK5, p38 MAPK, peripheral blood biomarkers, and the corpus callosum.",
    "sources": [
      {
        "key": "1",
        "text": "https://academic.oup.com/hmg/article/18/23/4492/664197"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/acs.joc.1c01970"
      },
      {
        "key": "3",
        "text": "https://www.oncotarget.com/article/15085/text/"
      },
      {
        "key": "4",
        "text": "https://www.mdpi.com/1420-3049/22/8/1287"
      },
      {
        "key": "5",
        "text": "https://www.mdpi.com/2073-4425/12/11/1794"
      },
      {
        "key": "6",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/acn3.443"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Salamanders can breathe through their gills, lungs, skin, mouth, and throat. The process of breathing can differ from type to type of salamanders. Some salamanders breathe through their gills, while others breathe through their lungs. Salamanders primarily rely on their skin for respiration, which is thin and permeable, allowing oxygen to diffuse into their bloodstream and carbon dioxide to diffuse out. Salamanders that live on land lose their gills as they grow older. Salamander larvae breathe through their gills, while adult salamanders such as the lungless salamanders breathe through their skin and the lining of their mouth, which is called buccopharyngeal respiration. [1][2][3][4][5]",
    "sources": [
      {
        "key": "1",
        "text": "https://k12.libretexts.org/Bookshelves/Science_and_Technology/Life_Science_for_Middle_School_(CK-12)/10%3A_Vertebrates/10.8%3A_Salamanders"
      },
      {
        "key": "2",
        "text": "https://acuariopets.com/how-do-salamanders-breathe/"
      },
      {
        "key": "3",
        "text": "https://amphibianplanet.com/how-salamanders-breathe/"
      },
      {
        "key": "4",
        "text": "https://www.britannica.com/science/respiratory-system/Amphibians"
      },
      {
        "key": "5",
        "text": "https://www.burkemuseum.org/collections-and-research/biology/herpetology/all-about-amphibians/all-about-amphibians"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Salamanders possess a pair of lungs for active air breathing, but the lung respiration is fully operational only during the late stage of development, particularly after metamorphosis. Larval salamanders mainly exchange air through the gills and skin, thus sparing the developing lungs [1]. Therefore, salamanders breathe through their skin and gills during their larval stage. However, after metamorphosis, they switch to breathing through their lungs [1].",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/cpr.13369"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Several methods can be used to explain predictions from black box models in chemistry. One approach is to use explainable AI (XAI) to interpret the entire model at once or to explain an individual prediction[1][2][3]. Another method is to estimate the causal effect of each input variable or feature on the output variable[4]. Some popular ways to explain black box models include using partial dependence plots, permutation feature importance, and SHAP values[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://engineering.dynatrace.com/blog/understanding-black-box-ml-models-with-explainable-ai/"
      },
      {
        "key": "2",
        "text": "https://www.zdnet.com/article/explainable-ai-artificial-intelligence-a-guide-for-making-black-box-machine-learning-models-explainable/"
      },
      {
        "key": "3",
        "text": "https://link.springer.com/chapter/10.1007/978-3-030-79108-7_8"
      },
      {
        "key": "4",
        "text": "https://ist.psu.edu/research/projects/black-box-predictive-models"
      },
      {
        "key": "5",
        "text": "https://www.elderresearch.com/blog/how-and-why-to-interpret-black-box-models/"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Black box models in chemistry, such as deep learning models, lack interpretability, which can make chemists skeptical of their use in decision making [1][2]. Explainable artificial intelligence (XAI) is a branch of AI that addresses this drawback by providing tools to interpret black box models and their predictions [1][2]. XAI methods like chemical counterfactuals and descriptor explanations can explain deep learning predictions while giving insight into structure-property relationships [1][2]. XAI methods can also be used to predict molecular properties and optimize molecular properties and synthetic pathways [3][4]. In addition, machine learning models can be combined with quantum chemistry to speed up the calculation of molecular properties while maintaining accuracy [5].",
    "sources": [
      {
        "key": "1",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/639222a114d92d7cd6a65e90"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jctc.2c01235"
      },
      {
        "key": "3",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/63e699bafcfb27a31f8dd492"
      },
      {
        "key": "4",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01789"
      },
      {
        "key": "5",
        "text": "https://pubs.acs.org/doi/abs/10.1021/cen-09714-scicon6"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "The input materials and energy required to use microorganisms for the synthesis of plastics depend on the specific process used. However, some general information can be found in the provided search results. For example, microbial electrosynthesis can reduce energy input compared to using water as an electron donor[1]. Photosynthesis is a process that uses light energy to construct glucose molecules from water and carbon dioxide, which can provide energy and fixed carbon for organisms[2][3]. Some bio-based monomers and polymers can be synthesized using microbes[4]. Synthetic biology has the potential to enable sustainable manufacturing of chemicals, including plastics, using microbes[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/nrmicro2422/"
      },
      {
        "key": "2",
        "text": "https://www.britannica.com/science/photosynthesis"
      },
      {
        "key": "3",
        "text": "https://www.khanacademy.org/science/ap-biology/cellular-energetics/photosynthesis/a/intro-to-photosynthesis"
      },
      {
        "key": "4",
        "text": "https://www.sciencedirect.com/science/article/abs/pii/S096085242101498X"
      },
      {
        "key": "5",
        "text": "https://www.nature.com/articles/s41587-022-01248-8"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Microbial synthesis of plastics from renewable resources has attracted considerable attention in recent years [1]. Polyesters such as polyethylene terephthalate (PET) are amenable to biological degradation due to the action of microbial polyester hydrolases [2]. The hydrolysis products obtained from PET can be used for the synthesis of novel PET as well as become a potential carbon source for microorganisms [2]. Microorganisms and biomass can also be used for the synthesis of the constituent monomers of PET from renewable sources [2]. The use of microalgal biomass as a feedstock for PHA synthesis presents a low-cost solution [3]. Activated sludge processes can be used for treating wastewater and producing PHAs [4]. The energy required for microbial synthesis of plastics can be generated from renewable resources [1]. Therefore, the materials required input to use microorganisms for synthesis of plastics include renewable carbohydrate sources, microorganisms, biomass, and energy from renewable resources.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/anie.200301655"
      },
      {
        "key": "2",
        "text": "https://www.mdpi.com/2073-4425/10/5/373"
      },
      {
        "key": "3",
        "text": "https://www.frontiersin.org/articles/10.3389/fbioe.2022.879476/full"
      },
      {
        "key": "4",
        "text": "https://www.mrforum.com/product/9781644901335-6/"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "perplexity",
    "date": "2023-04-10",
    "answer": "Birds flock together for various reasons, including safety, warmth, and finding food[1][2][3][4]. Flocking can help birds avoid predators, share body heat, and locate food sources more efficiently. Flocking behavior can also be a way for birds to socialize and communicate with each other. The coordinated movements of birds in a flock are thought to be the result of each bird following simple rules based on the movements of its neighbors[5].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://theconversation.com/why-do-flocks-of-birds-swoop-and-swirl-together-in-the-sky-a-biologist-explains-the-science-of-murmurations-176194"
      },
      {
        "key": "2",
        "text": "https://www.psychologytoday.com/us/blog/creating-connection/202012/why-do-birds-flock-together"
      },
      {
        "key": "3",
        "text": "https://news.yahoo.com/why-flocks-black-birds-suddenly-160130498.html?fr=sycsrp_catchall"
      },
      {
        "key": "4",
        "text": "https://www.columbia-audubon.org/birds-in-big-numbers-flocks-of-blackbirds-and-starlings/"
      },
      {
        "key": "5",
        "text": "https://earthsky.org/earth/how-do-flocking-birds-move-in-unison/"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Birds flock for various reasons, including foraging efficiency, predation avoidance, and social behavior [1]. Mixed-species flocks of birds involve species with different roles and foraging strategies and are ubiquitous in forest environments [1]. The diversity of foraging strategies occurring in a mixed flock reflects the diversity of participant species [1]. One of the main benefits of participating in mixed-species flocks is increased foraging efficiency [1]. However, feeding benefits remain under debate, probably because not all participants receive this benefit in the same way [1]. Species roles can broadly be categorized into leaders that attract others to form the flock, as well as lead the flock's movement; and follower species [1]. The predator avoidance hypothesis suggests that birds in mixed flocks increase their vigilance levels and decrease their predation risk [2]. The foraging efficiency hypothesis suggests that birds in mixed flocks increase their foraging efficiency and/or can spend more time feeding and less time looking out for predators [3]. The social behavior hypothesis suggests that birds flock for social reasons, such as to find mates or to learn from other birds [4]. In conclusion, birds flock for various reasons, including foraging efficiency, predation avoidance, and social behavior, and mixed-species flocks involve species with different roles and foraging strategies [1].",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/ibi.13162"
      },
      {
        "key": "2",
        "text": "https://link.springer.com/article/10.1007/s10164-004-0124-4"
      },
      {
        "key": "3",
        "text": "https://onlinelibrary.wiley.com/doi/10.1111/btp.12551"
      },
      {
        "key": "4",
        "text": "https://www.tandfonline.com/doi/abs/10.1080/00306525.1989.9639611"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods. One method is the thermal decomposition of a ferrocenyl compound in the presence of a multi(ethynyl)aromatic compound [1]. Another method is the use of an arc-jet plasma of high temperature to decompose methane [2]. Ethanol thermal reduction process can also be used to synthesize carbon nanotubes on a large scale [3]. The flame method is another simple method that can be used to synthesize carbon nanotubes [4]. Large-scale production of carbon nanotubes can also be achieved by using millimeter-diameter spheres as growth substrates [5]. The method described in [1] permits the large-scale production of carbon nanotubes in a shaped, solid configuration. The carbon nanotubes form under atmospheric pressure during the carbonization process above 500 \u00b0C in the carbonaceous solid. The Fe atoms, nanoclusters, and/or nanoparticles formed from the decomposition of the ferrocenyl compound are the key to the formation of the carbon nanotubes in the developing carbonaceous solid by reacting with the developing polycondensed aromatic ring system. The arc-jet plasma process described in [2] is continuous and easily scalable, making it a promising technique for the large-scale commercial production of carbon nanotubes. The optimal operating condition for the production of high purity multi-walled carbon nanotubes was found in this study. The ethanol thermal reduction process described in [3] uses ethanol as the carbon source and magnesium as the reductant. This method avoids the use of toxic or corrosive reagents and can potentially be applied on the scale of industrial production. The flame method described in [4] is a new and simple method that may have the possibility of large-scale mass production for the synthesis of carbon nanotubes. It needs not the vacuum environment and carbon nanotubes can be captured at the normal atmospheric pressure. The use of millimeter-diameter spheres as growth substrates for the large scale and continuous production of aligned carbon nanotube arrays is reported in [5]. This technique is more productive than the conventional process on flat wafers because of the higher available growth surface and the good fluidity of the spherical substrates. In conclusion, there are various methods for the large-scale production of carbon nanotubes, including thermal decomposition, arc-jet plasma, ethanol thermal reduction, flame method, and the use of millimeter-diameter spheres as growth substrates. Each method has its advantages and disadvantages, and the choice of method depends on the specific application and requirements.",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.acs.org/doi/10.1021/jp0665527"
      },
      {
        "key": "2",
        "text": "https://www.sciencedirect.com/science/article/abs/pii/S1567173905001926?via%3Dihub"
      },
      {
        "key": "3",
        "text": "https://pubs.acs.org/doi/10.1021/ja035763b"
      },
      {
        "key": "4",
        "text": "https://www.scientific.net/AMR.1048.383"
      },
      {
        "key": "5",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/cvde.200704249"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "scite",
    "date": "2023-04-10",
    "answer": "CD38 is a transmembrane glycoprotein that is highly expressed in almost all myeloma cells, making it an attractive treatment target [1]. Bispecific antibodies targeting CD38 and CD3 have been developed as a therapeutic strategy for multiple myeloma [2]. These antibodies recruit effector T cells to CD38-expressing myeloma cells and induce antibody-dependent cell-mediated cytotoxicity (ADCC) [2]. Anti-CD38 monoclonal antibodies have been approved for first-line treatment in non-transplantable multiple myeloma patients [1]. Isatuximab-irfc and daratumumab are examples of anti-CD38 monoclonal antibodies that have been approved for the treatment of multiple myeloma [4]. However, it has been found that anti-CD38 monoclonal antibodies bind to CD38 on red blood cells (RBCs) and cause pan agglutination in indirect antiglobulin test (IAT), resulting in false positives of IAT and thereby interfering with blood bank testing and leading to the delay of further diagnosis and treatment [1]. Bispecific CD38 antibodies have the potential to overcome the limitations of current therapies in patients with multiple myeloma by triggering the complete elimination of malignant multiple myeloma cells in patients, including low-expressing cells that may evade daratumumab, with the potential to induce profound clinical responses [3]. In conclusion, bispecific CD38 antibodies bind to CD38 on myeloma cells and recruit effector T cells to induce ADCC, making them an effective therapeutic strategy for multiple myeloma.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/jcla.23832"
      },
      {
        "key": "2",
        "text": "https://ashpublications.org/blood/article/128/22/2097/100388/The-Trifunctional-Antibody-tri-31C2-Targeting-CD38"
      },
      {
        "key": "3",
        "text": "https://aacrjournals.org/clincancerres/article/25/13/3921/81953/Targeting-Multiple-Myeloma-with-AMG-424-a-Novel"
      },
      {
        "key": "4",
        "text": "https://jamanetwork.com/journals/jama/article-abstract/2764168?utm_campaign=scite&utm_source=scite&utm_medium=referral"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "According to 1, the most promising way to produce carbon nanotubes on an industrial scale is through chemical vapor deposition (CVD). This process utilizes high energy (600\u2013900 \u00b0C [1,100\u20131,650 \u00b0F]) to atomize gaseous carbon sources, such as methane, carbon monoxide, and acetylene. The resulting reactive carbon atoms diffuse toward a catalyst-coated substrate and condense to form carbon nanotubes.\n\nAnother method used for manufacturing carbon nanotubes is laser ablation which uses a high-power laser to vaporize a graphite source loaded with a metal catalyst. The carbon in the graphite reforms as predominantly single-wall nanotubes on the metal catalyst particles 2.",
    "sources": [
      {
        "key": "1",
        "text": "Can Carbon Nanotube Transistors Be Scaled Down to the Sub-5 nm Gate Length? | ACS Applied Materials & Interfaces"
      },
      {
        "key": "2",
        "text": "Large-Scale Carbon Nanotube Production | Research and Innovation | Western Michigan University (wmich.edu)"
      },
      {
        "key": "3",
        "text": "Carbon Nanotube Manufacturing on a Commercial Scale - Ready for Mass-Markets (azonano.com)"
      },
      {
        "key": "4",
        "text": "Carbon nanotube | Properties & Uses | Britannica"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "Bispecific CD38 antibodies are designed to bind to two different molecules at the same time: CD38 and CD3 1. CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells 2. The binding of bispecific CD38 antibodies to CD38 on MM cells can activate T cells to kill MM cells 1.\n\nAccording to 3, daratumumab is a human IgG1\u03ba monoclonal antibody that binds to CD38. It is approved for the treatment of multiple myeloma in combination with other therapies. Daratumumab has been shown to induce rapid and deep responses in patients with relapsed/refractory multiple myeloma 3.",
    "sources": [
      {
        "key": "1",
        "text": "ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma | Blood | American Society of Hematology (ashpublications.org)"
      },
      {
        "key": "2",
        "text": "Bispecific Antibodies in Multiple Myeloma: Present and Future - PMC (nih.gov)"
      },
      {
        "key": "3",
        "text": "Bispecific Antibodies in Multiple Myeloma: Present and Future | Blood Cancer Discovery | American Association for Cancer Research (aacrjournals.org)"
      },
      {
        "key": "4",
        "text": "CD38 antibodies in multiple myeloma: back to the future - PubMed (nih.gov)"
      },
      {
        "key": "5",
        "text": "Antibodies and bispecifics for multiple myeloma: effective effector therapy | Hematology, ASH Education Program | American Society of Hematology (ashpublications.org)"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "As of 2022, there are several therapeutics available or being researched for ALS. According to 1, Relyvrio is a combination of two drugs, sodium phenylbutyrate and taurursodiol, which act to prevent nerve cell death by blocking stress signals in cells. The FDA approved RELYVRIO for use to treat ALS in 2022 2.\n\nBrainstorm Cell Therapeutics has announced that the Biologics License Application for NurOwn\u00ae for the treatment of ALS will be discussed in an upcoming FDA Advisory Committee Meeting 3.\n\nCoya Therapeutics has reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS) 4.\n\nDenali Therapeutics has announced new DNL343 (eIF2B Agonist) Phase 1b Data in ALS to be presented at the upcoming AAN Annual Meeting 5.",
    "sources": [
      {
        "key": "1",
        "text": "FDA-Approved Drugs for Treating ALS | The ALS Association"
      },
      {
        "key": "2",
        "text": "FDA Approval of Amyotrophic Lateral Sclerosis (ALS) Drug Represents Progress, But We\u2019re Not Done | National Institute of Neurological Disorders and Stroke (nih.gov)"
      },
      {
        "key": "3",
        "text": "BrainStorm Cell Therapeutics Inc.: Brainstorm Cell Therapeutics Announces Full Year 2022 Financial Results And Provides A Corporate Update (finanznachrichten.de)"
      },
      {
        "key": "4",
        "text": "There Is No Cure For ALS, But Coya Therapeutics Might Have T... | MENAFN.COM"
      },
      {
        "key": "5",
        "text": "Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting (tmcnet.com)"
      },
      {
        "key": "6",
        "text": "Promising ALS Therapy Moves Closer to Clinic | Columbia University Irving Medical Center"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "There are several software available for clustering protein structures output from a molecular dynamics trajectory. According to 1, MD-TASK is a software suite for analyzing molecular dynamics trajectories that can be used to cluster protein structures. It determines the physical motions of atoms of a biological macromolecule in a cell-like environment and is an important method in structural bioinformatics.\n\nAnother software is Bio3D which is an R package containing utilities for the analysis of protein structure, sequence and trajectory data 2.",
    "sources": [
      {
        "key": "1",
        "text": "Clustering Protein Structures with Hadoop | SpringerLink"
      },
      {
        "key": "2",
        "text": "An R package for structural bioinformatics \u2022 Bio3D (thegrantlab.org)"
      },
      {
        "key": "3",
        "text": "Fuzzy cluster analysis of molecular dynamics trajectories - Gordon - 1992 - Proteins: Structure, Function, and Bioinformatics - Wiley Online Library"
      },
      {
        "key": "4",
        "text": "Clustering Molecular Dynamics Trajectories for Optimizing Docking Experiments (hindawi.com)"
      },
      {
        "key": "5",
        "text": "Machine learning/molecular dynamic protein structure prediction approach to investigate the protein conformational ensemble | Scientific Reports (nature.com)"
      },
      {
        "key": "6",
        "text": "Molecular Dynamics - Introduction to cluster computing - Bioinformatics Documentation (melbournebioinformatics.org.au)"
      },
      {
        "key": "7",
        "text": "Clustering a protein from multiple independent copies \u2013 AMBER-hub (utah.edu)"
      },
      {
        "key": "8",
        "text": "MD-TASK: a software suite for analyzing molecular dynamics trajectories | Bioinformatics | Oxford Academic (oup.com)"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "There are several factors that should be considered when selecting a catalyst for a Diels-Alder reaction. According to 1, one of the factors is the impact of catalysts on the Diels\u2013Alder reaction. The model reaction was carried out using different catalysts such as AlCl3, FeCl3, Ca (OTf)2, CaCl2 and Bu4NPF6 and it was observed that Ca (OTf)2 furnished the best yield of Diels\u2013Alder adduct.\n\nAnother factor is asymmetric catalysis which involves the preparation of mono (2,6-dimethoxybenzoyl)tartaric acid and its use as boronic acid catalyst (BLn*) for a Diels-Alder reaction 2.",
    "sources": [
      {
        "key": "1",
        "text": "Lewis acid catalyst system for Diels\u2013Alder reaction | SpringerLink"
      },
      {
        "key": "2",
        "text": "1.1: Asymmetric Catalysis of Diels-Alder Reactions - Chemistry LibreTexts"
      },
      {
        "key": "3",
        "text": "Electrostatic catalysis of a Diels\u2013Alder reaction | Nature"
      },
      {
        "key": "4",
        "text": "11.3.7 The Diels-Alder Reaction - Chemistry LibreTexts"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "According to a study 1, SMILES representation exhibits the best overall performance whereas SELFIES guarantee valid chemical structures. DeepSMILES perform in between SMILES and SELFIES. InChIs are not appropriate for the learning task.",
    "sources": [
      {
        "key": "1",
        "text": "Performance of chemical structure string representations for chemical image recognition using transformers - Digital Discovery (RSC Publishing) DOI:10.1039/D1DD00013F"
      },
      {
        "key": "2",
        "text": "Molecular graph representations and SELFIES: A 100% robust molecular string representation (substack.com)"
      },
      {
        "key": "3",
        "text": "[1905.13741] Self-Referencing Embedded Strings (SELFIES): A 100% robust molecular string representation (arxiv.org)"
      },
      {
        "key": "4",
        "text": "Self-referencing embedded strings (SELFIES): A 100% robust molecular string representation - IOPscience"
      },
      {
        "key": "5",
        "text": "SELFIES and the future of molecular string representations - ScienceDirect"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "One promising biomarker and therapeutic target is the aggregatin protein, which attaches to amyloid-beta. Various RNA regulators could also be biomarkers or therapeutic targets. Genomic and transcriptomic studies comparing Alzheimer\u2019s disease and healthy states will advance this area and further the understanding of the disease pathology 1.",
    "sources": [
      {
        "key": "1",
        "text": "Alzheimer\u2019s Disease: How to Discover New Therapeutic Targets to Treat It (labiotech.eu)"
      },
      {
        "key": "2",
        "text": "Potential new treatment target for Alzheimer's disease -- ScienceDaily"
      },
      {
        "key": "3",
        "text": "Alzheimer\u2019s APOE4 Genetic Risk Targeted in Promising Trial - The New York Times (nytimes.com)"
      },
      {
        "key": "4",
        "text": "Study reveals a promising therapeutic target for Alzheimer's disease (news-medical.net)"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "Salamanders breathe either through their gills, lungs, or skin and thin membranes in their mouth and throat. Most salamanders start their lives with gills but develop lungs as they mature into adults. Some adult salamanders do not develop lungs, but instead mature to breathe entirely through their skin 1.",
    "sources": [
      {
        "key": "1",
        "text": "How Do Salamanders Breathe? [It Might Surprise You] (amphibianplanet.com)"
      },
      {
        "key": "2",
        "text": "Can Salamanders Breathe Underwater? [Answered] \u2013 Amphibian Planet"
      },
      {
        "key": "3",
        "text": "How Do Salamanders Breathe? \u2013 Acuario Pets"
      },
      {
        "key": "4",
        "text": "Respiratory system - Amphibians | Britannica"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "One approach to explain black box predictions is to fit a self-explaining or interpretable model to the black box model, in the vicinity of one or a few specific examples. These are known as surrogate models. We will make one model per explanation. If we could find one that explained the whole model, then we would simply have a globally accurate interpretable model and no longer need the black box model 1.\n\nAnother approach is feature attribution methods which explain black box predictions by assigning each input feature a numerical value which indicates its importance or contribution to the prediction. These atom-based numerical assignments are commonly referred to as heatmaps 1. The most widely used feature attribution approaches in literature are gradient-based methods, Shapley Additive explanations (SHAP), and layerwise relevance propagation 1.",
    "sources": [
      {
        "key": "1",
        "text": "a-perspective-on-explanations-of-molecular-prediction-models.pdf (chemrxiv.org)"
      },
      {
        "key": "2",
        "text": "A Perspective on Explanations of Molecular Prediction Models | Theoretical and Computational Chemistry | ChemRxiv | Cambridge Open Engage"
      },
      {
        "key": "3",
        "text": "Explanations of Black-Box Model Predictions by Contextual Importance and Utility | SpringerLink"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "Microorganisms can be used to synthesize bioplastics which are moldable plastic materials made up of chemical compounds that are derived from or synthesized by microbes such as bacteria or by genetically modified plants 1. These bioplastics are obtained from renewable resources and some bioplastics are biodegradable 1. Polyesters that are widely distributed in nature and accumulate intracellularly in microorganisms in the form of storage granules can also be used to synthesize plastics",
    "sources": [
      {
        "key": "1",
        "text": "Bioplastic | Definition & Facts | Britannica"
      },
      {
        "key": "2",
        "text": "Bioplastics from microorganisms - ScienceDirect"
      },
      {
        "key": "3",
        "text": "Can microorganisms solve our plastic waste problem? \u2013 DW \u2013 04/27/2020"
      },
      {
        "key": "4",
        "text": "Plastics and the microbiome: impacts and solutions | Environmental Microbiome | Full Text (biomedcentral.com)"
      },
      {
        "key": "5",
        "text": "Could plastic-eating microbes take a bite out of the recycling problem? | Science | AAAS"
      },
      {
        "key": "6",
        "text": "New approaches for the characterization of plastic-associated microbial communities and the discovery of plastic-degrading microorganisms and enzymes - ScienceDirect"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "bing",
    "date": "2023-04-11",
    "answer": "Birds flock for many reasons such as reducing fatigue in the members of the flock and a large or strong bird will take the lead 1. Birds also flock to replace a lost member of the flock 1. Sick birds will also flock together 1. Fatigue is another reason why birds flock together 1. Resistance is another reason why birds flock together 1.",
    "sources": [
      {
        "key": "1",
        "text": "Why do birds flock together? \u2013 How It Works (howitworksdaily.com)"
      },
      {
        "key": "2",
        "text": "Why do flocks of birds swoop and swirl together in the sky? A biologist explains the science of murmurations (theconversation.com)"
      },
      {
        "key": "3",
        "text": "Why Do Birds Flock Together? | Psychology Today"
      },
      {
        "key": "4",
        "text": "Birds and how they flock with Dr Karl | National Geographic (natgeokids.com)"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Carbon nanotubes (CNTs) are cylindrical molecules that consist of rolled-up sheets of single-layer carbon atoms\n1\n. They have many desirable properties such as high strength, low weight, energy and fuel storage capability, electron emission capability, and advantageous thermal, chemical, and surface properties\n2\n. There are several methods for manufacturing carbon nanotubes at scale, including:\nChemical vapor deposition (CVD): This is the most widely used method for producing carbon nanotubes at scale. It involves the use of a catalyst to decompose a hydrocarbon gas into carbon and hydrogen, which then react to form carbon nanotubes\n1\n3\n.\nArc discharge: This method involves the use of a high-voltage electric arc to vaporize graphite electrodes in a vacuum chamber. The resulting carbon vapor condenses into carbon nanotubes\n1\n.\nLaser ablation: This method uses a high-power laser to vaporize a graphite target in a vacuum chamber. The resulting carbon vapor condenses into carbon nanotubes\n4\n.\nSuper-growth method: This is a new method for synthesizing single-walled carbon nanotubes. It involves the use of a substrate coated with a liquid-metal catalyst, which forms an ideal surface for single-walled carbon nanotube growth when placed in a furnace fed with a slightly moist gas stream. The activity of this catalyst is several hundred times higher than for conventional growth methods\n5\n.\nContinuous inclined mobile-bed rotating reactor: This is a large-scale industrial manufacturing process that uses very active catalysts and methane or ethylene as a carbon source\n3\n.\nDespite the advances in carbon nanotube manufacturing, the formation of byproducts containing impurities such as metal encapsulated nanoparticles, metal particles in the tip of a carbon nanotube, and amorphous carbon has been an unavoidable phenomenon\n1\n. Therefore, purification is an essential step in the manufacturing process to obtain high-purity carbon nanotubes.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nanowerk.com/nanotechnology/introduction/introduction_to_nanotechnology_22.php"
      },
      {
        "key": "2",
        "text": "https://wmich.edu/research/large-scale"
      },
      {
        "key": "3",
        "text": "https://link.springer.com/article/10.1007/s11705-017-1635-1"
      },
      {
        "key": "4",
        "text": "https://link.springer.com/article/10.1007/s11705-017-1635-1"
      },
      {
        "key": "5",
        "text": "https://www.azonano.com/article.aspx?ArticleID=1108"
      },
      {
        "key": "6",
        "text": "https://www.nature.com/articles/d42473-022-00107-z"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods, with catalytic chemical vapor deposition (CCVD) being the most widely used method for processing CNTs (Pirard2017LargescaleIM pages 2-2). Large-scale industrial manufacturing of carbon nanotubes is achieved through the use of continuous inclined mobile-bed rotating reactors via the CCVD process (Pirard2017LargescaleIM pages 9-9). This type of reactor is particularly well-suited to the large ratio between the product and catalyst volumes (Pirard2017LargescaleIM pages 6-7). Fluidized-bed reactors have also been adopted worldwide for the commercial production of agglomerated CNTs (Pirard2017LargescaleIM pages 2-3).\n\nVarious synthesis and CNT characterization methods are employed, including TEM image analysis, adsorption of krypton and nitrogen, XRD, Raman, and photoluminescence, thermogravimetry, X-ray microtomography, and electrochemistry (Pirard2017LargescaleIM pages 6-7). The production of carbon nanotubes can also involve catalytic decomposition of hydrocarbons, using cobalt-supported catalysts, and using aluminum hydroxide-based catalytic materials (Pirard2017LargescaleIM pages 8-8).\n\nOverall, the large-scale manufacturing of carbon nanotubes relies on the development of continuous production processes that provide consistently high-quality output at a commercially viable cost (Pirard2017LargescaleIM pages 2-2)",
    "sources": [
      {
        "key": "1",
        "text": "https://link.springer.com/article/10.1007/s11705-017-1635-1"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "Carbon nanotubes can be manufactured at a large scale using several techniques such as **electric-arc technique**, **chemical vapor deposition (CVD)** and **laser ablation**\u00b2\u00b3. The electric-arc technique involves creating an arc between two electrodes in a reactor under a helium atmosphere and using a mixture of a metallic catalyst and graphite powder in the anode\u00b9. CVD is the most promising way to produce carbon nanotubes on an industrial scale. This process utilizes high energy (600\u2013900 \u00b0C [1,100\u20131,650 \u00b0F]) to atomize gaseous carbon sources, such as methane, carbon monoxide, and acetylene\u00b2. Laser ablation was first employed to produce carbon nanotubes in 1995\u00b2.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.britannica.com/science/carbon-nanotube"
      },
      {
        "key": "2",
        "text": "https://en.wikipedia.org/wiki/Synthesis_of_carbon_nanotubes"
      },
      {
        "key": "3",
        "text": "https://pypi.org/project/paper-qa/"
      }
    ]
  },
  {
    "question": "How can carbon nanotubes be manufactured at scale?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "Carbon nanotubes can be manufactured at scale using various methods. One method is the chemical vapor deposition (CVD) method, which involves the decomposition of hydrocarbons over a catalyst at high temperatures. This method has been used for large-scale production of carbon nanotubes [7]. Another method is the flame method, which is a simple and new method that has the potential for large-scale mass production of carbon nanotubes [3]. Column chromatography has also been used for the large-scale production of single chirality single-walled carbon nanotubes [1]. Other methods include laser vaporization, arc discharge, and pyrolysis [2]. Additionally, microfluidic hydrodynamic focusing has been used for the patterning and alignment of a large scale of carbon nanotubes [4]. The use of liquefied petroleum gas as a carbon source and ceramic spheres as substrates has also been shown to be a low-cost method for large-scale production of carbon nanotube arrays [5]. The continuous process of carbon nanotube synthesis using an arc-jet plasma has also been shown to be a promising technique for large-scale commercial production of carbon nanotubes [6]. Overall, there are various methods for manufacturing carbon nanotubes at scale, each with its own advantages and limitations.",
    "sources": [
      {
        "key": "1",
        "text": "https://onlinelibrary.wiley.com/doi/10.1002/pssb.201700279"
      },
      {
        "key": "2",
        "text": "https://pubs.aip.org/aip/apl/article-abstract/76/17/2367/111213/Controlling-the-diameter-growth-rate-and-density?redirectedFrom=fulltext"
      },
      {
        "key": "3",
        "text": "https://www.scientific.net/AMR.1048.383"
      },
      {
        "key": "4",
        "text": "https://www.scientific.net/AMR.194-196.503"
      },
      {
        "key": "5",
        "text": "https://link.springer.com/article/10.1007/s11434-007-0458-8"
      },
      {
        "key": "6",
        "text": "https://linkinghub.elsevier.com/retrieve/pii/S0040609005012174"
      },
      {
        "key": "7",
        "text": "https://iopscience.iop.org/article/10.1143/JJAP.45.4883"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Bispecific CD38 antibodies are designed to bind both CD38, a surface glycoprotein highly expressed on multiple myeloma (MM) cells, and CD3, a protein on the surface of T-cells[1]. This binding leads to T-cell activation and tumor cell killing[2]. Bispecific antibodies represent a new treatment option for patients with myeloma, and have shown impressive results in relapsed refractory myeloma[2]. The first bispecific agent, teclistamab, received regulatory approval in 2022[2]. Pacanalotamab (AMG 420, BI 836909) is another bispecific antibody developed for myeloma treatment, and it binds both BCMA (on MM cells) and CD3 (on cytotoxic T cells) [3]. Bispecific antibodies are designed to target antigens that are unique and specific to multiple myeloma cells, with minimal expression in other healthy tissues[1]. CD38 antibodies are highly effective in MM treatment because of their marked activity as single agents and in combinations, as well as their manageable toxicity profile[4]. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them[5].",
    "sources": [
      {
        "key": "1",
        "text": "https://aacrjournals.org/bloodcancerdiscov/article/2/5/423/665839/Bispecific-Antibodies-in-Multiple-Myeloma-Present"
      },
      {
        "key": "2",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046900/"
      },
      {
        "key": "3",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623099/"
      },
      {
        "key": "4",
        "text": "https://ashpublications.org/blood/article/131/1/13/107710/CD38-antibodies-in-multiple-myeloma-back-to-the"
      },
      {
        "key": "5",
        "text": "https://www.managedhealthcareexecutive.com/view/bispecific-antibodies-for-multiple-myeloma-are-on-their-way"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Bispecific CD38 antibodies, such as Bi38-3, are designed to target both CD38-expressing multiple myeloma (MM) cells and CD3-expressing T cells. By binding to both targets, these antibodies facilitate the recruitment of T cells to the MM cells, leading to T-cell-mediated cytotoxicity and the killing of the tumor cells (Fayon2020Bi383IA pages 1-1, Fayon2020Bi383IA pages 1-2). Bi38-3 has been shown to efficiently control MM tumor progression in vivo without significant toxicity against cells expressing intermediate levels of CD38, such as hematopoietic progenitors, B, T, or NK cells (Fayon2020Bi383IA pages 2-3).\n\nOther bispecific CD38 antibodies, like AMG 424, are optimized for cytotoxicity and cytokine release (Zafra2019TargetingMM pages 3-3). In some cases, bispecific heavy chain antibodies (hcAbs) can inhibit the GDPR-cyclase activity of CD38, which may contribute to changing a \"cold\" into a \"hot\" tumor microenvironment (Hambach2022TargetingMM pages 5-6). The principle of a biparatopic hcAb could be extended to a bispecific hcAb, in which two nanobodies with specificities for two different tumor markers are combined in one construct (Hambach2022TargetingMM pages 5-6).\n\nIn summary, bispecific CD38 antibodies bind and treat myeloma by targeting both CD38-expressing MM cells and CD3-expressing T cells, leading to T-cell-mediated cytotoxicity and tumor cell killing.",
    "sources": [
      {
        "key": "1",
        "text": "https://aacrjournals.org/clincancerres/article/25/13/3921/81953/Targeting-Multiple-Myeloma-with-AMG-424-a-Novel"
      },
      {
        "key": "2",
        "text": "https://haematologica.org/article/view/9809"
      },
      {
        "key": "3",
        "text": "https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005800/full"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "Bispecific CD38 antibodies are a type of bispecific T-cell engager (BiTE) antibody that binds to both CD38 and CD3 on T cells. This binding activates T cells to attack and kill CD38-expressing cancer cells, including multiple myeloma cells. Bispecific CD38 antibodies are used in the treatment of multiple myeloma\u00b9. Daratumumab is a monoclonal antibody specific for CD38 that has been incorporated into both frontline and relapsed treatment regimens since its approval by the US Food and Drug Administration in 2015\u00b9. Noteworthy naked monoclonal antibodies include isatuximab, another agent directed against CD38\u00b9. Additionally, bispecific T-cell antibodies are in development that engage the immune system directly by simultaneously binding CD3 on T cells and a target epitope\u2014such as BCMA, G-protein coupled receptor family C group 5 member D (GPRC5d), and Fc receptor homologue 5 (FcRH5)\u2014on malignant cells\u00b9. Currently, teclistamab, an anti-BCMA bispecific, is closest to approval for commercial use\u00b9.",
    "sources": [
      {
        "key": "1",
        "text": "https://ashpublications.org/hematology/article/2022/1/163/493531/Antibodies-and-bispecifics-for-multiple-myeloma"
      },
      {
        "key": "2",
        "text": "https://pubmed.ncbi.nlm.nih.gov/36614086/"
      },
      {
        "key": "3",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405888/"
      },
      {
        "key": "4",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510808/"
      },
      {
        "key": "5",
        "text": "https://www.myeloma.org/emerging-therapies/bispecific-therapies"
      }
    ]
  },
  {
    "question": "What do bispecific CD38 antibodies bind to and how do they treat myeloma?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "Bispecific CD38 antibodies bind to CD38, a transmembrane glycoprotein that is a tumor-associated antigen with near-universal expression in multiple myeloma [2][3][7]. These antibodies are designed to recruit T cells to cancer cells, triggering T-cell-redirected lysis, which is a clinically validated mechanism of action against hematologic malignancies [2][7]. Bispecific CD38 antibodies have been shown to display potent complement-dependent cytotoxicity against multiple myeloma cells [1]. They have also been found to have multiple modes of action for treating lymphoma and multiple myeloma [4]. Bispecific CD38 antibodies, including CD38 x ICAM1 and anti-CD38 x anti-CD3 bispecific antibodies, have demonstrated improved efficacy and specificity toward CD38+ and ICAM1+ tumor cells [5][6]. Bispecific CD38 antibodies are being explored as potential new powerful therapeutics for the treatment of multiple myeloma and other hematological malignancies and nonhematological diseases [1][3][6][8].",
    "sources": [
      {
        "key": "1",
        "text": "https://www.frontiersin.org/articles/10.3389/fimmu.2018.02553/full"
      },
      {
        "key": "2",
        "text": "https://aacrjournals.org/clincancerres/article/25/13/3921/81953/Targeting-Multiple-Myeloma-with-AMG-424-a-Novel"
      },
      {
        "key": "3",
        "text": "https://www.frontiersin.org/articles/10.3389/fonc.2022.1007783/full"
      },
      {
        "key": "4",
        "text": "https://aacrjournals.org/cancerres/article/82/12_Supplement/5385/703476/Abstract-5385-Multiple-modes-of-action-of-the-CD38"
      },
      {
        "key": "5",
        "text": "https://ashpublications.org/blood/article/138/Supplement%201/2413/478530/CD38-x-ICAM1-Bispecific-Antibody-Is-a-Novel"
      },
      {
        "key": "6",
        "text": "https://academic.oup.com/abt/article/4/4/212/6383648"
      },
      {
        "key": "7",
        "text": "https://aacr.figshare.com/collections/Data_from_Targeting_Multiple_Myeloma_with_AMG_424_a_Novel_Anti-CD38_CD3_Bispecific_T-cell_recruiting_Antibody_Optimized_for_Cytotoxicity_and_Cytokine_Release/6528261/1"
      },
      {
        "key": "8",
        "text": "https://aacrjournals.org/cancerres/article/82/12_Supplement/2903/700379/Abstract-2903-ISB-1442-a-first-in-class-CD38-and"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "As of 2022, there are several therapeutics available or being researched for ALS. Here are some of the key ones from the search results:\nFDA-Approved Drugs\nRiluzole: This drug has been approved by the FDA to treat ALS and can slow the progression of the disease by a few months\n1\n.\nEdaravone: This drug has also been approved by the FDA to treat ALS and can prolong survival by a few months\n1\n.\nRELYVRIO: This is a combination of two drugs, sodium phenylbutyrate and taurursodiol, which act to prevent nerve cell death by blocking stress signals in cells. The FDA approved RELYVRIO for use to treat ALS in 2022\n2\n.\nDrugs Being Trialed\nAMX0035: This is a combination of two drugs, sodium phenylbutyrate and taurursodiol, which act to prevent nerve cell death by blocking stress signals in cells. It has shown potent therapeutic effects in clinical trials and has been approved by the FDA for the treatment of ALS\n3\n.\nMethylcobalamin: This drug has shown promise in clinical trials for treating ALS\n3\n.\nMasitinib: This drug has shown promise in clinical trials for treating ALS\n3\n.\nCNM-Au8: This drug has shown promise in clinical trials for treating ALS\n3\n.\nTofersen: This drug has shown promise in clinical trials for treating ALS\n3\n.\nOther Therapies\nStem cell therapy: Stem cell therapy is being investigated as a potential treatment option for ALS\n4\n5\n.\nOccupational therapy: Occupational therapy can help manage symptoms and improve the quality of life for those with ALS\n4\n.\nGene therapy: Gene therapy is being investigated as a potential treatment option for ALS\n4\n.\nSmall molecule therapy: Recent studies have focused on identifying small molecules that can promote the survival of motor neurons and reduce inflammation\n4\n.\nImmunomodulation therapy: Studies have shown that inflammation plays a vital role in the progression of ALS. Some recent studies have focused on the use of immunomodulation therapy to reduce inflammation and improve the survival of motor neurons\n4\n.\nArimoclomol: This drug is currently undergoing clinical trials and is being investigated as a potential treatment option for ALS\n6\n.\nInsulin-like growth factor-1 (IGF-1): This drug is currently undergoing clinical trials and is being investigated as a potential treatment option for ALS\n5\n6\n.\nRAPA-501 autologous T cells: This therapy is currently undergoing clinical trials and is being investigated as a potential treatment option for ALS\n5\n6\n.\nIt's important to note that while some of these therapies have shown promise in clinical trials, they are still being investigated and have not yet been approved by the FDA for the treatment of ALS.",
    "sources": [
      {
        "key": "1",
        "text": "https://pubmed.ncbi.nlm.nih.gov/36518658/"
      },
      {
        "key": "2",
        "text": "https://www.als.org/navigating-als/living-with-als/fda-approved-drugs"
      },
      {
        "key": "3",
        "text": "https://www.frontiersin.org/articles/10.3389/fphar.2022.1054006/full"
      },
      {
        "key": "4",
        "text": "https://www.dvcstem.com/post/stem-cells-als"
      },
      {
        "key": "5",
        "text": "https://pharmanewsintel.com/features/exploring-fda-approved-drugs-and-potential-treatment-options-for-als"
      },
      {
        "key": "6",
        "text": "https://vial.com/blog/articles/innovations-in-als-research-clinical-trials-for-emerging-therapies/"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "As of 2022, there is no cure for ALS, and therapeutic options aim to slow the progression of the disease and provide symptomatic relief (Roberts2022SynucleinopathyIA pages 9-10). Riluzole and edaravone are the only two drugs approved by the FDA for ALS, with riluzole being the most widely used (Roberts2022SynucleinopathyIA pages 9-10). Pain management is crucial, and non-steroidal anti-inflammatory drugs, opioids, and occasionally medicinal cannabis are used for severe pain (Roberts2022SynucleinopathyIA pages 9-10). Therapeutic exercise and physiotherapy are recommended to slow symptomatic progression and alleviate pain (Roberts2022SynucleinopathyIA pages 9-10). In the later stages of the disease, interventions to manage weight loss and malnutrition are fundamental (Roberts2022SynucleinopathyIA pages 9-10).\n\nSeveral therapeutics are being researched for ALS, including antisense oligonucleotide (AO) therapies (Roberts2022SynucleinopathyIA pages 12-12). Ionis Pharmaceuticals has developed ASOs against three targets for ALS: BIIB078 for C9ORF72, jacifusen for FUS, and tofersen for SOD1 (Holm2022ClinicalAO pages 8-8). Tofersen, an investigational ASO targeting the gene encoding SOD1, is currently in a phase III trial (Holm2022ClinicalAO pages 8-8). However, results from a 28-week initial study with 108 enrolled patients living with SOD1-ALS receiving either tofersen or placebo failed to meet the primary endpoint of change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (Holm2022ClinicalAO pages 8-8).\n\nOther emerging therapeutic modalities for ALS include gene therapies, viral vector deliveries, and targeting TAR DNA-binding protein of 43 kDa (TDP-43) (Roberts2022SynucleinopathyIA pages 22-23; Maragakis2022TheEL pages 2-3). The development of new preclinical models and systems based on human cells derived from actual patients has expanded the possibilities of candidate cellular targets for new drugs (Maragakis2022TheEL pages 1-1). Targeting motor neuron cell death and nuclear pore dysfunction as a core mechanism for ALS may become an important target for effective interventions (Maragakis2022TheEL pages 1-1).\n\nIn summary, while there is no cure for ALS, riluzole and edaravone are FDA-approved drugs for the disease, and various therapeutics, such as AO therapies and gene therapies, are being researched to develop more effective treatments.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.tandfonline.com/doi/full/10.1080/15476286.2022.2066334"
      },
      {
        "key": "2",
        "text": "https://www.mdpi.com/1422-0067/23/16/9364"
      },
      {
        "key": "3",
        "text": "https://link.springer.com/article/10.1007/s13311-022-01307-7"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to the current web page context, there are currently seven drugs approved by the U.S. Food and Drug Administration (FDA) to treat ALS and its symptoms: Qalsody, RELYVRIO, Radicava, Rilutek, Tiglutik, Exservan and Nuedexta\u00b9. RELYVRIO is a combination of two drugs, sodium phenylbutyrate and taurursodiol, which act to prevent nerve cell death by blocking stress signals in cells. The FDA approved RELYVRIO for use to treat ALS in 2022\u00b9. Radicava\u2122 (edaravone) was approved in 2017, making it the first new treatment specifically for ALS in 22 years. An oral formulation was approved in 2022\u00b9. Rilutek (riluzole) was the first FDA-approved drug available to treat ALS \u2014 in 1995. It inhibits glutamate release and prolongs life approximately three months\u00b9. ",
    "sources": [
      {
        "key": "1",
        "text": "https://www.als.org/navigating-als/living-with-als/fda-approved-drugs "
      },
      {
        "key": "2",
        "text": "https://www.ninds.nih.gov/news-events/directors-messages/all-directors-messages/fda-approval-amyotrophic-lateral-sclerosis-als-drug-represents-progress-were-not-done"
      },
      {
        "key": "3",
        "text": "https://www.frontiersin.org/articles/10.3389/fnagi.2022.914017/full "
      },
      {
        "key": "4",
        "text": "www.cuimc.columbia.edu/news/promising-als-therapy-moves-closer-clinic"
      }
    ]
  },
  {
    "question": "What therapeutics are available or being researched for ALS as of 2022?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "As of 2022, there is no effective therapeutic for ALS [4]. However, there are several drugs that are being researched for ALS treatment. Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment with modest benefits on survival [1]. Recently, edaravone and AMX0035 have also been approved by the FDA for the treatment of ALS [5]. Other drugs in clinical development for ALS include AT-1501, CNM-Au8, Engensis, Pridopidine, Verdiperstat, and Zilucoplan [3]. In addition to drug therapies, emerging ALS therapies in pre-clinical or early clinical development include gene therapy, immunotherapy, and strategies that target neuroinflammation, phase separation, and protein clearance [2]. However, recent clinical trials have shown that a reappraisal of strategies to identify therapeutic targets for ALS is required [6].",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1002/med.21528"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.12703/b/9-12"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.51731/cjht.2022.274"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.1021/ml500404b"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.3389/fphar.2022.1054006"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.1159/000089627"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "To cluster protein structures output from a molecular dynamics trajectory, there are several methods available. Here are some examples from the search results:\n\n1. **Coordinate RMSD**: One commonly used distance metric is coordinate RMSD. This method groups similar conformations together based on the distance metric, where the smaller the distance, the more similar the structures[1].\n2. **Cluster Analysis**: Cluster analysis is a commonly used way to partition data into structurally distinct states. There are several clustering algorithms available, such as k-means, dbscan, and hierarchical clustering[1][2].\n3. **Orientation and Conformation**: For systems where both molecular orientation and conformation are important, there are cluster analysis methods specifically designed for these types of systems[3].\n4. **Validation**: Validating clustering of molecular dynamics simulations using polymer models is another method that focuses on partitioning structural ensembles into groups of structures which are similar to each other[4].\n5. **CATBOSS**: CATBOSS is a method that improves on the state of the art in clustering analysis. It is a clustering algorithm that is based on segment splitting[2].\n6. **Other algorithms**: There are several other clustering algorithms available that can be applied to the analysis of protein molecular dynamics, such as agglomerative hierarchical clustering, affinity propagation, and spectral clustering[5].",
    "sources": [
      {
        "key": "1",
        "text": "https://amberhub.chpc.utah.edu/clustering-a-protein-trajectory/"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jcim.1c00598"
      },
      {
        "key": "3",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925300/"
      },
      {
        "key": "4",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284309/"
      },
      {
        "key": "5",
        "text": "https://www.researchgate.net/publication/323063665_Clustering_algorithms_applied_on_analysis_of_protein_molecular_dynamics"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "There are several approaches for clustering protein conformations in molecular dynamics simulations. One approach is based on pre-calculated distance matrices and uses average-link hierarchical clustering to construct a tree hierarchy of pathway axes based on their pairwise distances (Chovancov\u00e12012CAVER3A pages 4-4). The size of the clusters may be optimized by cutting the tree at a varying level of detail. Another approach is a fast approximate algorithm based on supervised machine learning, which enables the classification of even larger datasets with hundreds of thousands of pathways (Chovancov\u00e12012CAVER3A pages 4-4). A set of pathways of manageable size is randomly sampled from the pathway dataset and clustered using the average-link hierarchical clustering. Each pathway is then assigned to one of the N+1 classes, where N classes correspond to the N clusters with the highest priority, and the last class contains pathways belonging to all remaining clusters.\n\nIn addition to these approaches, other algorithms for clustering protein conformations in molecular dynamics simulations have been discussed in literature, such as the ones described by Y. Loewenstein et al. in \"Efficient Algorithms for Accurate Hierarchical Clustering of Huge Datasets: Tackling the Entire Protein Space\" and J.L. Klepeis et al.'s paper \"Long-timescale Molecular Dynamics Simulations of Protein Structure and Function\" (Pavelka2016CAVERAF pages 14-14). Another example includes the use of CAVER 3.0 and MOLE 1.2 clustering algorithms in the analysis of transport pathways in dynamic protein structures (Chovancov\u00e12012CAVER3A pages 10-10).\n\nIn conclusion, clustering protein structures output from a molecular dynamics trajectory can be achieved using various approaches such as average-link hierarchical clustering, supervised machine learning, or other specialized algorithms. The choice of method depends on the specific requirements and size of the dataset in question.",
    "sources": [
      {
        "key": "1",
        "text": "https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1002708"
      },
      {
        "key": "2",
        "text": "https://ieeexplore.ieee.org/document/7164312"
      },
      {
        "key": "3",
        "text": "https://academic.oup.com/nar/article/48/W1/W17/5826170?login=false"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to the current web page context, clustering protein structures output from a molecular dynamics trajectory can be done using different methods. One of the most common methods is clustering based on root-mean-square deviation (RMSD) of the protein backbone atoms. Other methods include clustering based on the distance between residues or clustering based on the secondary structure of the protein\u00b2. There are also web-based tools available to share interactive representations of 3D biomolecular structures and molecular dynamics trajectories\u00b9.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/s41598-022-13714-z"
      },
      {
        "key": "2",
        "text": "https://www.frontiersin.org/articles/10.3389/fmolb.2021.726232/full"
      },
      {
        "key": "3",
        "text": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133172"
      }
    ]
  },
  {
    "question": "How can I cluster protein structures output from a molecular dynamics trajectory?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "There are several methods to cluster protein structures output from a molecular dynamics trajectory. One common approach is to use RMSD-based clustering, which groups similar structures based on their root-mean-square deviation (RMSD) values [1]. Another method is cluster analysis, which involves obtaining representative models from the trajectory and assessing their geometry and stereochemical quality [2]. Wordom is a user-friendly program that provides tools for investigating biomolecule flexibility and detecting structural deformations [3]. Fuzzy clustering is another method that can be used to analyze molecular dynamics trajectories, especially of proteins and polypeptides [5]. Additionally, CAVER provides algorithms for analyzing the dynamics of tunnels in macromolecules and includes an improved clustering solution for finding tunnels [6]. Finally, machine learning techniques such as support vector machines (SVM) and clustering can be used to uncover differences between configurational data from molecular dynamics simulations [4].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.3762/bxiv.2021.50.v1"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1002/jcb.28013"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1016/j.csbj.2023.01.026"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.3389/fmolb.2019.00042"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.1002/prot.340140211"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.1109/tcbb.2015.2459680"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, several factors should be considered. Here are some insights from the search results:\n\n- **Catalyst type**: The type of catalyst used can have a significant impact on the reaction outcome. For example, Lewis acids and non-covalent interactions can be used as catalysts[1], as well as chiral oxazaborolidinium cations[2].\n\n- **Substrate**: The choice of substrate can also affect the reaction outcome. Different dienes and dienophiles can be used, and the regioselectivity of the reaction can be influenced by the substitution pattern of the diene[2].\n\n- **Hydrophobicity**: The hydrophobic effect can provide a driving force for association of the reactants, which is increased on hydrophobic surfaces in water[3].\n\n- **Enantioselectivity**: The enantioselectivity of the reaction can be influenced by the choice of catalyst. For example, Corey's cationic oxazaborolidine catalysts can be used for enantioselective Diels-Alder reactions[4].\n\n- **Catalyst position**: The position of the catalyst can also affect the reaction outcome. For example, in hetero-Diels-Alder reactions, the catalyst can be positioned at the dienophile or the diene[1].\n\n- **Molecular orbital overlap**: The occupied \u03c0-MOs of diene and dienophile responsible for the main part of the Pauli repulsion energy term, and their occupied-occupied MO overlap values can also affect the reaction outcome[1].\n\nOverall, the choice of catalyst for a Diels-Alder reaction should be based on the specific reaction conditions and desired outcome.\n",
    "sources": [
      {
        "key": "1",
        "text": "https://www.mdpi.com/1422-0067/24/5/4938"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/ja049323b"
      },
      {
        "key": "3",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685102/"
      },
      {
        "key": "4",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631179/"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, factors to consider include the catalyst's ability to enhance reaction rates and selectivities, its influence on endo:exo or ortho/para isomer selectivity, and its potential for heterogenization, which can offer advantages in handling, separation, and recycling (Matuszek2016SilicasupportedCI pages 2-2). Comparative studies of different metal chlorides as catalysts can provide guidance for selecting the best chlorometallate ionic liquids (Matuszek2016SilicasupportedCI pages 3-4). Additionally, the performance of the catalyst in terms of conversion and endo:exo selectivity should be considered (Matuszek2016SilicasupportedCI pages 1-2). Supported catalysts can offer benefits such as reduced reaction time, high conversions, and high endo-selectivity without the need for cooling the reaction below ambient temperature (Matuszek2016SilicasupportedCI pages 7-8).",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.rsc.org/en/content/articlelanding/2016/CY/C6CY01771A"
      },
      {
        "key": "2",
        "text": "https://www.science.org/doi/10.1126/science.aae0010"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to the current web page context, factors that should be considered for selecting a catalyst for a Diels-Alder reaction include the Lewis acidity of the catalyst, the steric bulk of the catalyst, and the ability of the catalyst to stabilize the transition state\u00b9. In general, Diels-Alder reactions proceed fastest with electron-donating groups on the diene (eg. alkyl groups)\u00b9. ",
    "sources": [
      {
        "key": "1",
        "text": "https://bing.com/search?q=factors+for+selecting+a+catalyst+for+a+Diels-Alder+reaction"
      },
      {
        "key": "2",
        "text": "https://link.springer.com/article/10.1007/s12039-020-1749-8"
      },
      {
        "key": "3",
        "text": "https://www.sciencedirect.com/science/article/pii/S2451945616300964"
      }
    ]
  },
  {
    "question": "What factors should I consider for selecting a catalyst for a Diels-Alder reaction?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "When selecting a catalyst for a Diels-Alder reaction, several factors should be considered. One of the most important factors is the enantioselectivity of the catalyst, which determines the stereochemistry of the product. Catalysts such as conformationally constrained bis(oxazoline) derived chiral catalysts [1], salts of imidazolidinones or TADDOLs [2], C2-symmetric bipyrrolidines [3], and oxazaborolidinone [6] have been reported to be highly effective in achieving high enantioselectivity in Diels-Alder reactions. Another factor to consider is the reactivity of the catalyst, which affects the rate of the reaction. Carbocations such as Ph3C+ [4] and NbCl5 [8] have been reported to be efficient catalysts for Diels-Alder reactions. The selectivity of the catalyst is also important, as it determines the regiochemistry of the product. Catalysts such as diarylprolinol silyl ether [5] and MacMillan catalyst modified with ionic liquid [7] have been reported to provide exo-selective Diels-Alder products. Additionally, the type of reaction being performed, such as aza-Diels-Alder reactions, may require specific catalysts such as chiral Br\u00f8nsted acid catalysts [10] or amino acid derivatives [9]. Overall, the selection of a catalyst for a Diels-Alder reaction should consider factors such as enantioselectivity, reactivity, selectivity, and the type of reaction being performed.",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1016/0040-4039(96)00721-6"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1021/ar3000822"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1002/chin.201015082"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.1002/chin.201427035"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.1002/chin.200747027"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.1021/jo702043g"
      },
      {
        "key": "7",
        "text": "https://doi.org/10.1039/c5ra09710j"
      },
      {
        "key": "8",
        "text": "https://doi.org/10.5151/chempro-15bmos-bmos2013_201387221042"
      },
      {
        "key": "9",
        "text": "https://doi.org/10.1002/anie.200500811"
      },
      {
        "key": "10",
        "text": "https://doi.org/10.1021/ja064676r"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "According to the search results, SELFIES and SMILES are both molecular graph representations that aim to map a string of tokens to a molecular graph. However, SELFIES are a newer representation that has been shown to be more robust and can represent every molecule[1][2]. SELFIES can be directly applied in arbitrary machine learning models without the adaptation of the models, and each of the generated molecule candidates is valid[1]. In experiments, the model's internal memory stores two orders of magnitude more diverse molecules than a similar test with SMILES[3]. SELFIES can be used as a direct input to deep learning models, such as variational autoencoders (VAEs) and generative adversarial networks (GANs) [4]. \n\nOn the other hand, SMILES have been a significant workhorse over the decades in chemoinformatics and can encode several molecules' spatial features[5]. However, SMILES face significant issues in the era of machine learning in chemistry, and it is easier for machines to \u201cunderstand\u201d SELFIES (compared to other string-based representations such as SMILES and DeepSMILES) [5]. \n\nIn terms of which representation is better, it depends on the specific application. According to a tweet by Andrew White, SELFIES are great for generating macrocycles, while SMILES are better for small molecule generation[6].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://iopscience.iop.org/article/10.1088/2632-2153/aba947"
      },
      {
        "key": "2",
        "text": "https://www.sciencedirect.com/science/article/pii/S2666389922002069"
      },
      {
        "key": "3",
        "text": "https://arxiv.org/abs/1905.13741"
      },
      {
        "key": "4",
        "text": "https://grlearning.github.io/papers/59.pdf"
      },
      {
        "key": "5",
        "text": "https://aspuru.substack.com/p/molecular-graph-representations-and"
      },
      {
        "key": "6",
        "text": "https://twitter.com/andrewwhite01/status/1621923392885559303"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Based on the provided context, it is evident that both SELFIES and SMILES have been used in deep learning molecular representation. In the study by Rajan2020DECIMERTD (pages 5-7), it was found that DeepSMILES outperformed SMILES, and SELFIES further outperformed DeepSMILES in terms of average Tanimoto similarity and Tanimoto 1.0 percentage. However, the authors mentioned that the indication of SELFIES outperforming DeepSMILES is \"preliminary,\" and further research is needed to confirm this finding.\n\nThe other sources provided do not offer a direct comparison between the performance and applicability of SELFIES and SMILES in deep learning for molecular representation (Rajan2020DECIMERTD pages 3-4, Zhu2021SteppingBT pages 12-12, Rajan2020DECIMERTD pages 9-9, Zhu2021SteppingBT pages 9-10).\n\nIn conclusion, while preliminary results suggest that SELFIES may outperform SMILES in deep learning molecular representation, more research is needed to determine the definitive advantages and disadvantages of using each representation system.",
    "sources": [
      {
        "key": "1",
        "text": "https://jcheminf.biomedcentral.com/articles/10.1186/s13321-020-00469-w"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to a research paper published in the Royal Society of Chemistry, the SMILES representation exhibits the best overall performance whereas SELFIES guarantee valid chemical structures. DeepSMILES perform in between SMILES and SELFIES, InChIs are not appropriate for the learning task\u00b9. Another research paper published on arXiv.org states that SELFIES can be directly applied in arbitrary machine learning models without the adaptation of the models; each of the generated molecule candidates is valid. In their experiments, the model's internal memory stores two orders of magnitude more diverse molecules than a similar test with SMILES\u00b2.",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.rsc.org/en/content/articlehtml/2022/dd/d1dd00013f"
      },
      {
        "key": "2",
        "text": "https://arxiv.org/abs/1905.13741"
      },
      {
        "key": "3",
        "text": "https://www.nature.com/articles/s42256-021-00418-8"
      },
      {
        "key": "4",
        "text": "https://pubs.rsc.org/en/content/articlepdf/2021/sc/d1sc00231g"
      }
    ]
  },
  {
    "question": "Are SELFIEs or SMILES a better representation of molecules for deep learning?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "According to the references, there is no clear consensus on whether SELFIEs or SMILES are a better representation of molecules for deep learning. Reference [2] suggests that DeepSMILES are superior to SMILES, but SELFIES may outperform DeepSMILES. Reference [4] indicates that SMILES-based representation has better performance than SELFIES. However, Reference [1] states that SELFIES can represent every molecule and are 100% robust, while Reference [5] suggests that SELFIES are better at generating a variety of molecules than traditional representations. Additionally, Reference [3] mentions a surjective alternative to SMILES that may have potential for other techniques. Therefore, it seems that the choice of representation may depend on the specific application and the goals of the deep learning model.\n",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1088/2632-2153/aba947"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1186/s13321-020-00469-w"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1088/2632-2153/ac09d6"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.1093/bfgp/elad012"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.5121/csit.2023.130303"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "There are several promising targets for Alzheimer's disease, other than ABeta. Here are some of them:\n\n1. Tau protein: Tau protein is another hallmark of Alzheimer's disease, and its buildup in the brain can lead to the formation of neurofibrillary tangles. Targeting tau protein is a promising approach for developing new treatments for Alzheimer's[1].\n\n2. Neuroinflammation: Inflammation in the brain can contribute to the development and progression of Alzheimer's disease. Targeting neuroinflammation is a potential strategy for developing new treatments[1].\n\n3. Immune response: The immune system plays a role in Alzheimer's disease, and targeting the immune response is a potential approach for developing new treatments[1].\n\n4. Metabolic changes: Metabolic changes in the brain can contribute to the development of Alzheimer's disease. Targeting these changes is a potential strategy for developing new treatments[1].\n\n5. Multi-target approach: A multi-target approach involves targeting multiple aspects of Alzheimer's disease simultaneously. This approach has shown promise in recent studies[2].\n\n6. Lifestyle habits: Lifestyle habits, such as eating a healthy diet, may reduce a person's risk for cognitive decline and dementia. While there isn't a single food, ingredient, or supplement that has been shown to prevent, treat, or cure Alzheimer's or other dementias, research suggests that lifestyle habits may have a positive impact[1].\n\n7. Cyclohexanehexol: Cyclohexanehexol is a compound that has been shown to prevent oligomerization in vitro and alleviate AD symptoms in animal models[3].\n\n8. Saracatinib: Saracatinib is a drug that was initially developed as a possible cancer treatment but is now being tested in Alzheimer's disease[4].\n\n9. ApoE: ApoE is a protein that plays a role in the development of Alzheimer's disease. Targeting ApoE is a potential strategy for developing new treatments[5].\n\n10. Heart disease: Research is looking more closely at how the connection between heart disease and Alzheimer's works at the molecular level to find new drug targets[4].\n\n11. Combination therapy: Future Alzheimer's treatments may include a combination of medications, similar to how treatments for many cancers or HIV/AIDS include more than a single drug[4].\n\n12. Amyloid and tau pathologies: There is consensus that both amyloid and tau pathologies should be targeted in Alzheimer's disease, as well as additional targets[6].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://www.alz.org/help-support/i-have-alz/treatments-research"
      },
      {
        "key": "2",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864545/"
      },
      {
        "key": "3",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140224/"
      },
      {
        "key": "4",
        "text": "https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780"
      },
      {
        "key": "5",
        "text": "https://alzres.biomedcentral.com/articles/10.1186/s13195-021-00927-z"
      },
      {
        "key": "6",
        "text": "https://link.springer.com/article/10.14283/jpad.2022.29"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Promising targets for Alzheimer's disease other than A\u03b2 include tau, triggering receptor expressed on myeloid cells-2 (TREM2), CD38, Toll-like receptors (TLRs), gut microbiota, autophagy, SIRT5, exercise, and the central cholinergic system, particularly acetylcholinesterase (AChE) (Song2022ImmunotherapyFA pages 1-2; Ma2022AmyloidosisIA pages 11-12; Song2022ImmunotherapyFA pages 11-12; Ma2022AmyloidosisIA pages 10-10; Ma2022AmyloidosisIA pages 4-4). Other potential therapeutic approaches include the use of natural compounds derived from plants, such as Paeonia alba, and anti-A\u03b2 single-chain variable fragments, like scFv-h3D6 (Ma2022AmyloidosisIA pages 7-8). Some of these targets are currently being investigated in clinical trials, such as TREM2 antibody AL002, tau antibody JNJ-63733657, and daratumumab targeting CD38 (Song2022ImmunotherapyFA pages 11-12). Additionally, sodium oligomannate, a drug that remodels gut microbiota and suppresses neuroinflammation, has recently received conditional approval in China (Song2022ImmunotherapyFA pages 17-17).",
    "sources": [
      {
        "key": "1",
        "text": "https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-022-00292-3"
      },
      {
        "key": "2",
        "text": "https://www.mdpi.com/1420-3049/27/4/1210"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to a research paper published on labiotech.eu, one promising biomarker and therapeutic target is the aggregating protein, which attaches to amyloid-beta. Various RNA regulators could also be biomarkers or therapeutic targets. Genomic and transcriptomic studies comparing Alzheimer\u2019s disease and healthy states will advance this area and further the understanding of the disease pathology\u00b9. Another research paper published on sciencedaily.com suggests that APOE4 is associated with the activation of an inflammatory protein that causes a breakdown in the blood-brain barrier which protects the brain. This research builds on a recent USC study that revealed APOE4 triggers leaks in the blood-brain barrier in humans, which lets toxic substances from the blood stream into the brain, damaging brain cells and disrupting cognitive functions. This process causes memory problems in patients whether or not their brain shows signs of amyloid-\u03b2, the sticky plaque peptide considered a hallmark of the disease. The latest findings also suggest a new potential treatment to slow down or prevent the cognitive decline associated with Alzheimer's disease in patients with the APOE4 gene, independently of amyloid-\u03b2 pathology\u00b2.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.labiotech.eu/partner/therapeutic-targets-alzheimers-disease/ "
      },
      {
        "key": "2",
        "text": "https://www.sciencedaily.com/releases/2021/06/210614131220.htm"
      },
      {
        "key": "3",
        "text": "https://pubmed.ncbi.nlm.nih.gov/34480965/"
      },
      {
        "key": "4",
        "text": "https://www.nature.com/articles/s41380-021-01251-6"
      }
    ]
  },
  {
    "question": "What are promising targets for Alzheimer's disease (other than ABeta)?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "There are several promising targets for Alzheimer's disease other than ABeta. One potential target is tau protein, which is involved in the formation of neurofibrillary tangles in the brain. Studies have shown that reducing endogenous tau can ameliorate ABeta-induced deficits in Alzheimer's disease mouse models [1]. Another potential target is somatostatin, which regulates ABeta42 through modulation of proteolytic degradation. Downregulation of somatostatin expression may trigger ABeta accumulation leading to late-onset sporadic Alzheimer's disease, and somatostatin receptors may be pharmacological-target candidates for prevention and treatment of Alzheimer's disease [2]. Acetylcholinesterase inhibitors (AChEIs) are another promising target, particularly dual binding site AChEIs, which are designed to target ABeta aggregation and other biological targets that contribute to Alzheimer's disease pathogenesis [3]. Beta- and gamma-secretases, which are responsible for the generation of ABeta, are also plausible molecular targets for Alzheimer's disease treatment [4][5]. Modulation of X11beta function is another potential therapeutic target for ABeta-mediated neuronal dysfunction in Alzheimer's disease [6]. Other strategies that have been investigated to target ABeta include secretase modulators and anti-polymerization agents [7]. Additionally, drugs that interfere with ABeta misfolding and aggregation hold great promise for the treatment of Alzheimer's disease [8]. Overall, treatment strategies targeting the formation, accumulation, or cytotoxic effects of ABeta should be pursued [9].",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1126/science.1141736"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1038/nm1206"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.2174/092986708785909067"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.2741/s322"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.1007/s00210-007-0206-2"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.1093/hmg/ddp408"
      },
      {
        "key": "7",
        "text": "https://doi.org/10.2165/00023210-200519120-00002"
      },
      {
        "key": "8",
        "text": "https://doi.org/10.2174/156802607779318262"
      },
      {
        "key": "9",
        "text": "https://doi.org/10.1001/archneur.58.12.2025"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Salamanders breathe in different ways depending on the species. Here are some ways that salamanders breathe:\n\n1. **Gills**: Some salamanders, such as sirens, keep their gills all their lives, which allows them to breathe underwater[1]. \n\n2. **Lungs**: Some salamanders have lungs, such as the California newt[2]. \n\n3. **Skin and mouth lining**: For decades, scientists have assumed that the hundreds of species of salamanders that lack lungs actually \u201cbreathe\u201d through their skin and the lining of the mouth[3]. Salamanders have a blood vessel that goes to the skin, which is not present in other animals, and there are also many enriched blood vessels that go to the buccal cavity[3]. It is believed that they pump air in and out of their mouth and throat by pulsing[3]. \n\n4. **Thin membranes in mouth and throat**: Salamanders can also breathe through thin membranes in their mouth and throat[4].\n\nIt is important to note that not all salamanders breathe in the same way, and some species may use a combination of these methods.\n",
    "sources": [
      {
        "key": "1",
        "text": "https://animals.sandiegozoo.org/animals/salamander-and-newt"
      },
      {
        "key": "2",
        "text": "https://news.openspaceauthority.org/blog/salamanders"
      },
      {
        "key": "3",
        "text": "https://news.harvard.edu/gazette/story/2019/01/lungless-salamanders-skin-expresses-protein-crucial-for-lung-function/"
      },
      {
        "key": "4",
        "text": "https://amphibianplanet.com/how-salamanders-breathe/"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Salamanders have a unique mode of respiration. They take in water through their nostrils, which is used to extract oxygen, and then release the water through their mouth (None pages 2-3). Additionally, salamanders rise to the surface of the water to breathe air directly into their lungs, similar to a frog (None pages 2-3). The salamander has numerous ridges or folds of the mucous membrane in the palatal region, which may have a respiratory function analogous to that of the gills of the same animals in the larval stage (None pages 2-3; None pages 3-3).",
    "sources": [
      {
        "key": "1",
        "text": "https://www.jstor.org/stable/3623747?origin=crossref"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to an article on amphibianplanet.com, when in the water, terrestrial salamanders cannot breathe air. They breathe entirely through their skin. Dissolved oxygen in the water is absorbed through their skin and into their bloodstream. At the same time, carbon dioxide from the bloodstream passes through their skin and diffuses into the water\u00b9. When on land, salamanders breathe either through their gills, lungs, or skin and thin membranes in their mouth and throat. Most salamanders start their lives with gills but develop lungs as they mature into adults. Some adult salamanders do not develop lungs but instead mature to breathe entirely through their skin\u00b2.",
    "sources": [
      {
        "key": "1",
        "text": "https://amphibianplanet.com/can-salamanders-breathe-underwater/"
      },
      {
        "key": "2",
        "text": "https://amphibianplanet.com/how-salamanders-breathe/"
      },
      {
        "key": "3",
        "text": "https://acuariopets.com/how-do-salamanders-breathe/"
      }
    ]
  },
  {
    "question": "How do Salamanders breathe?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "Lungless salamanders breathe through their skin and mouth lining, a process known as cutaneous respiration. They produce pulmonary surfactant-like secretions outside the lungs, which facilitate extrapulmonary respiration in the absence of lungs [2][3]. Small lungless salamanders consume more oxygen than small lunged salamanders, but large lunged salamanders consume more oxygen than large lungless salamanders [1]. Cutaneous gas exchange during activity is possible in small salamanders, but not in large salamanders, as the skin of large salamanders has a limited scope for aerobic activity [4]. Lungless salamanders have reduced atrial septation, which is a direct result of lunglessness [5]. Salamanders are insignificant agents for nutrient cycling in the ecosystem [6].\n",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1002/jez.1402020310"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1098/rspb.2018.1589"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1101/261412"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.1242/jeb.138.1.487"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.1111/joa.12535"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.2307/1936147"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "There are several methods that can be used to explain predictions from black box models in chemistry, according to the search results:\n\n1. **Feature attribution methods**: These methods explain black-box predictions by assigning each input feature a numerical value, which indicates its importance or contribution to the prediction. Feature attributions provide local explanations but can be averaged or combined to explain multiple instances[1].\n\n2. **Self-explaining or interpretable models**: One approach to explain black box predictions is to fit a self-explaining or interpretable model to the black box model, in the vicinity of one[2][3].\n\n3. **Ensemble models**: Ensemble models can be used to combine the predictions of multiple models, including black box models, to provide a more interpretable output[2].\n\n4. **Partial dependence plots**: These plots show how the predicted outcome changes as a function of a single input variable while holding all other inputs constant. They can be used to understand the relationship between input variables and the predicted outcome[2].\n\n5. **Local surrogate models**: These models are trained to approximate the behavior of the black box model in a local region of the input space. They can be used to provide local explanations of the black box model's predictions[2].\n\n6. **Sensitivity analysis**: Sensitivity analysis can be used to identify which input variables have the greatest impact on the predicted outcome. This can help to identify which variables are most important for understanding the black box model's predictions[2].\n\nIt is worth noting that some chemists may be skeptical of using black box models in decision making due to the lack of interpretability. However, the methods listed above can be used to provide explanations of the black box model's predictions[4].",
    "sources": [
      {
        "key": "1",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134429/"
      },
      {
        "key": "2",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jctc.2c01235"
      },
      {
        "key": "3",
        "text": "https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/639222a114d92d7cd6a65e90/original/a-perspective-on-explanations-of-molecular-prediction-models.pdf"
      },
      {
        "key": "4",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/639222a114d92d7cd6a65e90"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Several methods can be used to explain predictions from black-box models in chemistry. These include counterfactual explanations, descriptor explanations, regularization techniques such as EXPO and RRR, self-explaining models, attribution methods, gradient-based approaches, local approximations and Shapley values, similarity maps, graph neural networks, and deep learning (Wellawatte2023APO part 0; Wellawatte2023APO part 2; Wellawatte2023APO part 5; Wellawatte2023APO part 6). Specific methods mentioned include MMACE, Edge-SHAPer, LIMEtree, GraphLIME, and CF-GNNexplainer (Wellawatte2023APO part 3; Wellawatte2023APO part 6). The choice of method depends on the audience and the desired explanation outcomes, and it is crucial to evaluate the explanations to ensure their validity and usefulness in the given context (Wellawatte2023APO part 2).",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jctc.2c01235"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to a research paper published on ACS Publications, one approach to explain black-box predictions is to fit a self-explaining or interpretable model to the black-box model in the vicinity of one or a few specific examples. These are known as surrogate models. Generally, one model per explanation is trained. Feature attribution methods explain black box predictions by assigning each input feature a numerical value which indicates its importance or contribution to the prediction. These atom-based numerical assignments are commonly referred to as heatmaps\u00b9. Another research paper published on chemrxiv.org states that explainable artificial intelligence (XAI) is a branch of AI which addresses the lack of interpretability in \"black-box\" models by providing tools to interpret deep learning models and their predictions\u00b2.",
    "sources": [
      {
        "key": "1",
        "text": "https://pubs.acs.org/doi/10.1021/acs.jctc.2c01235"
      },
      {
        "key": "2",
        "text": "https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/639222a114d92d7cd6a65e90/original/a-perspective-on-explanations-of-molecular-prediction-models.pdf"
      },
      {
        "key": "3",
        "text": "https://chemrxiv.org/engage/chemrxiv/article-details/639222a114d92d7cd6a65e90"
      }
    ]
  },
  {
    "question": "What methods can be used to explain predictions from black box models in chemistry?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "There are several methods that can be used to explain predictions from black box models in chemistry. One approach is to use model-agnostic methods, which approximate the prediction of the black-box model with an interpretable model without considering any specifics of the black-box model itself [1]. Another method is to use explainer model methods such as LIME (local interpretable model-agnostic explanations), which provide explanations for predictions made by black-box models [2]. Additionally, some researchers have developed chemistry-intuitive explanations of graph neural networks for molecular property prediction with substructure masking [3]. Another approach is to use a universal model-agnostic approach that can explain any black-box model prediction [4]. Explainable Artificial Intelligence (XAI) has also received much attention recently, particularly for deep learning-based molecular property prediction [5]. An alternative approach is to explain black-box models through explaining individual prediction using a locally interpretable model [6]. Finally, some researchers suggest a two-step process of highly accurate black-box modeling and then creating explanations to give both highly accurate predictions and clear structure-property relationships [7].",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.3390/ai4020023"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1002/sam.11500"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1038/s41467-023-38192-3"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.33774/chemrxiv-2021-4qkg8-v2"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.26434/chemrxiv-2022-qt49t"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.48550/arxiv.1909.12367"
      },
      {
        "key": "7",
        "text": "https://doi.org/10.26434/chemrxiv-2022-qfv02"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Microorganisms can be used for the synthesis of biodegradable plastics. The materials and energy required for this process depend on the type of microorganism and the specific polymer being produced. Here are some key points from the search results:\n\n- Bioplastics are intracellularly accumulated by microorganisms as carbon and energy reserves[1].\n- Polyhydroxyalkanoates (PHAs) are synthesized and accumulated by many prokaryotic microorganisms as storage compounds for carbon and energy[2].\n- Bacterial polymers can be used to design cell factories for the production of tailor-made bio-based materials suitable for high-value applications[3].\n- Bioplastics can be manufactured from bio-based polymers, which are typically extracted or synthesized from biomass compounds such as sugars in plants[4].\n- Synthetic plastics are derived from crude oil, natural gas, or coal[5].\n- The energy required for the synthesis of bioplastics depends on the specific process being used. For example, the development of novel biodegradable plastics synthesized by using plant microbes to evolve to degrade plastics can reduce the energy required for the process[6].\n\nIn summary, the materials and energy required for the synthesis of biodegradable plastics using microorganisms depend on the specific process being used. However, bioplastics are generally produced using renewable and waste resources, which can reduce the environmental impact of plastic production.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889595/"
      },
      {
        "key": "2",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726165/"
      },
      {
        "key": "3",
        "text": "https://www.nature.com/articles/s41579-019-0313-3"
      },
      {
        "key": "4",
        "text": "https://www.nature.com/articles/s41578-021-00407-8"
      },
      {
        "key": "5",
        "text": "https://www.bpf.co.uk/plastipedia/how-is-plastic-made.aspx"
      },
      {
        "key": "6",
        "text": "https://journals.asm.org/doi/10.1128/aem.00721-22"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "I cannot provide a comprehensive answer on the specific materials and energy inputs necessary for microorganism-based plastic production based on the provided sources. However, it is worth noting that the use of mixed microbial cultures (MMCs) has been identified as a promising strategy to reduce energy inputs and costs associated with aeration and media and equipment sterilization in the production of polyhydroxyalkanoates (PHA) from biomass feedstocks and waste materials (Turco2021InVA pages 22-23).",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1007/978-3-642-03287-5_2"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1007/S13399-013-0094-2"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.3389/fbioe.2020.619266"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to an article on nature.com, bioplastics \u2014 typically plastics manufactured from bio-based polymers \u2014 stand to contribute to more sustainable commercial plastic life cycles as part of a circular economy, in which virgin polymers are made from renewable or recycled raw materials. Carbon-neutral energy is used for production and products are reused or recycled at their end of life (EOL). In this Review, we assess the advantages and challenges of bioplastics in transitioning towards a circular economy. Compared with fossil-based plastics, bio-based plastics can have a lower carbon footprint and exhibit advantageous materials properties; moreover, they can be compatible with existing recycling streams and some offer biodegradation as an EOL scenario if performed in controlled or predictable environments\u00b9. Another research paper published on ncbi.nlm.nih.gov states that polyhydroxyalkanoates (PHAs) are a family of microbial polyesters which comprise of a large family of thermoplastic polymers. They are produced by a variety of prokaryotic microorganisms under unbalanced nutrition conditions as carbon and energy storage materials\u00b3.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/s41578-021-00407-8"
      },
      {
        "key": "2",
        "text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761907/"
      },
      {
        "key": "3",
        "text": "https://www.britannica.com/science/photosynthesis"
      }
    ]
  },
  {
    "question": "What materials and energy are required input to use microorganisms for synthesis of plastics?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "To use microorganisms for the synthesis of plastics, various materials and energy inputs are required. Microorganisms and biomass can be used for the synthesis of the constituent monomers of PET from renewable sources [2]. Plastic mixtures containing various types of plastics, including fossil-based recalcitrant plastics and bioplastics, can be used as feedstock for microbial transformations [3]. The hydrolysis products obtained from PET can be used for the synthesis of novel PET as well as becoming a potential carbon source for microorganisms [4]. In addition, microbially produced polymers, which are synthesized from renewable carbon sources such as sugars and oils, are of interest for solving environment and resource problems [6]. The energy required for production and processing of bioplastics based on renewable resources is decisive, and the feedstock for generation of the overall energy is also required [1]. The ratio of nitrogen is determined largely by the maintenance requirements of microbes and the breakdown of microbial materials, which result in the recycling of microbial nitrogen [5]. Finally, to provide competitive alternatives to classical plastics, production of PHA biopolyesters has to become more economical [7].",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1002/anie.200301655"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.3390/genes10050373"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1186/s12302-021-00536-5"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.20944/preprints201904.0284.v1"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.3168/jds.s0022-0302(84)81409-5"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.1021/ma202285c"
      },
      {
        "key": "7",
        "text": "https://doi.org/10.1002/elsc.201300021"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Birds flock together for various reasons, including safety, foraging, and migration. Here are some details from the search results:\n\n1. **Safety**: A larger group of birds has a much better chance of spotting predators than a single bird. In addition, staying in a flock means it's harder for a predator to identify a single target and a group of birds can also confuse or overwhelm a predator through mobbing[1][2].\n2. **Foraging**: Flocking enables birds to fly further using less energy because when the strong leader bird flaps its wings, it creates uplift for the birds behind it. By flying in a V-formation, birds can take advantage of this uplift and reduce their energy expenditure[3].\n3. **Migration**: Avian flocks are typically associated with migration. By co-existing with one another in a flock, less time and energy is spent searching for predators. This mutual protection of one another within the flock is one of the benefits of living within a group[4].\n4. **Warmth**: Some birds, such as starlings, form murmurations, which are flocks that constantly change direction and shape. One theory is that spending the night together keeps the starlings warmer as they share their body heat. It might also reduce the chance an individual bird would be eaten overnight[5].\n\nIn summary, birds flock together for safety, foraging, migration, and warmth.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.rspb.org.uk/birds-and-wildlife/natures-home-magazine/birds-and-wildlife-articles/features/why-birds-flock-together/"
      },
      {
        "key": "2",
        "text": "https://www.wwt.org.uk/news-and-stories/blog/marvellous-murmurations-why-do-birds-flock-together/"
      },
      {
        "key": "3",
        "text": "https://www.howitworksdaily.com/why-do-birds-flock-together/"
      },
      {
        "key": "4",
        "text": "https://en.wikipedia.org/wiki/Flock_(birds)"
      },
      {
        "key": "5",
        "text": "https://theconversation.com/why-do-flocks-of-birds-swoop-and-swirl-together-in-the-sky-a-biologist-explains-the-science-of-murmurations-176194"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Birds flock for various reasons, including managing disturbance, foraging rates, economics of fleeing from predators, conveying information on threat, discrimination between predators, flight initiation distance, and refuges from predators (Morelli2019ContagiousFE pages 9-9). Flocking also provides anti-predator defense, increased foraging efficiency, and access to food resources (Sridhar2014UsingIA pages 11-12). In mixed-species flocks, many species obtain predation-related benefits, and the proportion of different foraging species might reflect the relative proportions of foraging resources in an area (Sridhar2014UsingIA pages 10-10). Gregarious behavior in birds affords a multiplicity of eyes, increasing the probability of sighting potential predators or prey, thus allowing for early defensive measures and increasing the probability of successful escape when encountering risk (Morelli2019ContagiousFE pages 3-4).",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1007/s00265-013-1633-3"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1002/ece3.5193"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to an article on howitworksdaily.com, there are several benefits to flying as a flock. It improves a bird\u2019s chance of survival against predators because a large group of birds is stronger and better protected and with many eyes the flock is far more likely to spot a would-be marauder. Flying in a V formation is a good way to reduce fatigue in the members of the flock and a large or strong bird will often lead the way. Each bird will benefit from the updraft created by the flapping of the bird in front\u2019s wings which makes flying easier. When the flock leader becomes tired, another bird will take its place\u00b9. Another article on natgeokids.com states that birds follow three simple rules: First, don\u2019t get too close to each other. This avoids collisions. Second, don\u2019t get too far away from another bird, or from the centre of the flock. But if you do drift out, head back in to the flock. Third, fly in a parallel direction. Head the same way as your neighbours\u00b2.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.howitworksdaily.com/why-do-birds-flock-together/"
      },
      {
        "key": "2",
        "text": "https://www.natgeokids.com/uk/discover/science/nature/birds-flock/"
      },
      {
        "key": "3",
        "text": "https://theconversation.com/why-do-flocks-of-birds-swoop-and-swirl-together-in-the-sky-a-biologist-explains-the-science-of-murmurations-176194"
      }
    ]
  },
  {
    "question": "Why do birds flock?",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "Birds flock for various reasons, including foraging, predator avoidance, and social interaction. Flocking behavior is a natural phenomenon that is formed and organized without central or external controls [4]. Flocking birds act coordinated according to a number of simple rules [3]. When a bird flock is looking for food, the simplest way for the bird flock is to seek the birds who are nearest to the food [1]. The model predicts that birds will flock, especially in the morning, if flocking birds find more food (\"foraging efficiency\"), and also more flocking can be expected when the predation risk is lower in a flock (\"antipredator benefit\") [5]. Bird species presented a higher flocking propensity and mixed flocks occurred more frequently during the dry and cold seasons than during the more benign seasons, and lower values of temperature within seasons triggered the flocking behavior [2]. The size (biomass) of bird\u2010flocks corresponds to the amount of food the birds kleptoparasitize from ant raids, and the heavier Pacific\u2010slope bird\u2010flocks could have greater negative kleptoparasitic impacts [6].",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.5194/isprsarchives-xxxix-b3-35-2012"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1111/btp.12551"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.11591/ijece.v6i6.pp2955-2961"
      },
      {
        "key": "4",
        "text": "https://doi.org/10.1155/2013/196823"
      },
      {
        "key": "5",
        "text": "https://doi.org/10.1007/bf00172172"
      },
      {
        "key": "6",
        "text": "https://doi.org/10.1111/btp.12452"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, list the hypothesized effects of stimulating or inhibiting them, and list the specific molecules that are most commonly used to define them.",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Here are three examples of specific, molecularly-defined populations of neurons in the brain that can be targeted to enhance brain function, along with their linked functions, hypothesized effects of stimulating or inhibiting them, and specific molecules that are commonly used to define them:\n\n1. **S1P receptor-expressing neurons**: S1P is a fat molecule that is believed to be responsible for chemo brain in people treated with chemotherapy[1]. S1P receptor-expressing neurons are found in areas of the brain responsible for functions like memory and information processing[1]. Stimulating or inhibiting these neurons could have an effect on chemo brain. Treatments that target the S1P receptor, which are already approved by the FDA to treat multiple sclerosis, have been shown to prevent chemo brain-like symptoms in mice[1].\n\n2. **BDNF-expressing neurons**: Brain-derived neurotrophic factor (BDNF) is a molecular factor that increases synaptogenesis, forming new connections between neurons and improving memory[2]. BDNF-expressing neurons are found in the hippocampus, a key memory region of the brain[2]. Exercise has been shown to increase BDNF levels, which can improve memory[2].\n\n3. **Immature, plastic neurons**: Immature, plastic neurons are present in significant numbers throughout the human hippocampus, a key memory region of the brain[3]. These neurons play a critical role in the brain's plasticity, or ability to change and adapt over time[3]. Stimulating or inhibiting these neurons could have an effect on learning and memory. Specific molecules that are commonly used to define these neurons include doublecortin and PSA-NCAM[3].\n\nNote that these are just a few examples of the many molecularly-defined populations of neurons in the brain that could be targeted to enhance brain function. Further research is needed to fully understand the functions and effects of these and other populations of neurons.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.cancer.gov/news-events/cancer-currents-blog/2022/chemo-brain-prevention-s1p"
      },
      {
        "key": "2",
        "text": "https://lifesciences.byu.edu/how-exercise-affects-your-brain"
      },
      {
        "key": "3",
        "text": "https://www.pennmedicine.org/news/news-releases/2022/july/discovery-of-molecular-signatures-of-immature-neurons-in-the-human-brain"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, list the hypothesized effects of stimulating or inhibiting them, and list the specific molecules that are most commonly used to define them.",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "Three molecularly-defined populations of neurons in the brain include:\n\n1. Dopamine neuronal subtypes in the hypothalamus: These neurons are involved in various hypothalamic functions such as feeding, reward, and sleep (Romanov et al., 2017). Stimulating or inhibiting these neurons may affect these behaviors and physiological processes. Specific molecules used to define these subtypes include single-cell RNA sequencing data (Romanov et al., 2017).\n\n2. Inhibitory neuronal subclasses marked by Lamp5, Sncg, Vip, Sst, or Pvalb: These neurons are distributed across isocortex, hippocampal formation, olfactory areas, and cortical subplate (Zhang2023AMD part 1). Their functions include inhibitory modulation of neural activity in these regions. Stimulating or inhibiting these neurons could alter the balance of excitation and inhibition in the brain, potentially affecting information processing and behavior. Specific molecules used to define these subclasses include the markers Lamp5, Sncg, Vip, Sst, and Pvalb (Zhang2023AMD part 1).\n\n3. Glutamatergic neurons expressing Vglut1 (Slc17a7), Vglut2 (Slc17a6), and Vglut3 (Slc17a8): These neurons are widely distributed across the whole brain and are involved in excitatory neurotransmission (Zhang2023AMD part 1). Stimulating or inhibiting these neurons could influence various brain functions, depending on the specific brain regions and circuits involved. Specific molecules used to define these neurons include the vesicular glutamate transporters Vglut1 (Slc17a7), Vglut2 (Slc17a6), and Vglut3 (Slc17a8) (Zhang2023AMD part 1).\n\nIn conclusion, molecularly-defined populations of neurons in the brain play diverse roles in neural function and behavior. Stimulating or inhibiting these neurons may have various effects depending on the specific cell types and brain regions involved. Specific molecules used to define these populations include single-cell RNA sequencing data and molecular markers such as neurotransmitter transporters and neuropeptides (Romanov et al., 2017; Zhang2023AMD part 1).",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1038/s41467-022-35574-x"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1101/2023.03.06.531348"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, list the hypothesized effects of stimulating or inhibiting them, and list the specific molecules that are most commonly used to define them.",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to an article on nature.com, one study identified 11 major projection neuron types with distinct morphological features and corresponding transcriptomic identities. Extensive projectional diversity was found within each of these major types. This diversity follows a set of generalizable principles that govern long-range axonal projections at different levels, including molecular correspondence, divergent or convergent projection, axon termination pattern, regional specificity, topography, and individual cell variability\u00b9. Another research paper published on nature.com states that quantifying the distribution of specific neurons throughout the whole brain is crucial for understanding physiological actions, pathological alterations and...\u00b2. Unfortunately I could not find a third reference that meets all the criteria you requested.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/s41586-021-03941-1"
      },
      {
        "key": "2",
        "text": "https://www.nature.com/articles/s41598-017-14699-w"
      },
      {
        "key": "3",
        "text": "https://www.nature.com/articles/s41586-021-03223-w"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, list the hypothesized effects of stimulating or inhibiting them, and list the specific molecules that are most commonly used to define them.",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "1. External segment of the globus pallidus (GPe) neurons:\n- Function: Involved in motor control and movement initiation.\n- Hypothesized effects of stimulating: Increased motor activity and movement initiation.\n- Hypothesized effects of inhibiting: Decreased motor activity and movement initiation.\n- Specific molecules used to define them: Parvalbumin (PV) and neuropeptide Y (NPY) [1].\n\n2. Sexually dimorphic neurons in the ventromedial hypothalamus:\n- Function: Involved in mating behavior and aggression in males.\n- Hypothesized effects of stimulating: Increased mating behavior and aggression in males and females.\n- Hypothesized effects of inhibiting: Decreased mating behavior and aggression in males and females.\n- Specific molecules used to define them: Estrogen receptor alpha (ER\u03b1) and calbindin (CB) [2].\n\n3. Neuronal populations derived from the preplate:\n- Function: Involved in the development of the central nervous system.\n- Hypothesized effects of stimulating: Increased neuronal development and differentiation.\n- Hypothesized effects of inhibiting: Decreased neuronal development and differentiation.\n- Specific molecules used to define them: X-Gal histochemical staining [3].",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1523/jneurosci.4646-13.2014"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1016/j.cell.2013.04.017"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1016/s0896-6273(04)00140-0"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, and list the hypothesized effects of stimulating or inhibiting them.",
    "model": "perplexity",
    "date": "2023-06-05",
    "answer": "Here are three specific, molecularly-defined populations of neurons in the brain that we could target in order to enhance brain function, along with their functions and the hypothesized effects of stimulating or inhibiting them:\n\n1. **Immature neurons in the hippocampus**: The hippocampus plays a major role in learning, memory, mood, behavior, and brain disorders. Immature, plastic neurons are present in significant numbers throughout the human hippocampus, and they are important for the brain's plasticity, or ability to change and adapt over time. Stimulating these neurons could potentially enhance the brain's ability to learn and adapt, while inhibiting them could potentially impair these functions[1].\n\n2. **Neurons in the cerebral cortex**: The cerebral cortex is responsible for many higher-level brain functions, including perception, attention, awareness, thought, memory, language, and consciousness. Stimulating or inhibiting specific populations of neurons in the cerebral cortex could potentially enhance or impair these functions, respectively. For example, stimulating neurons in the prefrontal cortex could potentially enhance working memory and decision-making, while inhibiting them could potentially impair these functions[2].\n\n3. **Neurons in the brainstem**: The brainstem is responsible for many basic life-sustaining functions, including breathing, heart rate, blood pressure, and digestion. Stimulating or inhibiting specific populations of neurons in the brainstem could potentially enhance or impair these functions, respectively. For example, stimulating neurons in the respiratory center of the brainstem could potentially enhance breathing, while inhibiting them could potentially impair this function[3].\n\nIt should be noted that these are just a few examples, and there are many other specific populations of neurons in the brain that could potentially be targeted to enhance brain function. Additionally, the effects of stimulating or inhibiting these neurons would likely depend on many factors, including the specific population of neurons, the method of stimulation or inhibition, and the individual's unique brain circuitry and physiology.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.pennmedicine.org/news/news-releases/2022/july/discovery-of-molecular-signatures-of-immature-neurons-in-the-human-brain"
      },
      {
        "key": "2",
        "text": "https://www.uclahealth.org/news/mind-over-matter-study-shows-we-consciously-exert-control-over-individual-neurons"
      },
      {
        "key": "3",
        "text": "https://www.alz.org/alzheimers-dementia/what-is-dementia"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, and list the hypothesized effects of stimulating or inhibiting them.",
    "model": "paperqa-2.1.0",
    "date": "2023-06-05",
    "answer": "One example of molecularly-defined populations of neurons is found in a study on mammalian spinal motor neurons. The single-cell transcriptomic analysis revealed 16 molecularly-defined populations of spinal motor neurons in mice (Liau2023SinglecellTA part 10). The authors hypothesize that some of these populations may be involved in specific motor functions, such as fine motor control or locomotion. They also suggest that inhibiting or stimulating specific populations could have therapeutic applications for motor neuron diseases (Liau2023SinglecellTA part 10).\n\nAlthough Paul2023StepwiseMS pages 24-25 does not directly mention other examples of molecularly-defined populations of neurons that can be targeted to modulate brain function and their hypothesized effects when stimulated or inhibited, the article discusses related studies that may provide insight. These studies include research on glutamate receptor targeting to synaptic populations on Purkinje cells, glutamate receptor \u03b42 subunit in activity-dependent heterologous synaptic competition, synapse type-specific proteomic dissection, transsynaptic modulation of kainate receptor functions by C1q-like proteins, synapse diversity and synaptome architecture in human genetic disorders, and developmental disruption and restoration of brain synaptome architecture in the murine Pax6 neurodevelopmental disease model (Paul2023StepwiseMS pages 24-25).\n\nIn conclusion, molecularly-defined populations of neurons, such as the 16 populations of spinal motor neurons identified in mice, can potentially be targeted to enhance brain function and treat motor neuron diseases (Liau2023SinglecellTA part 10). Further research is needed to explore additional examples and their potential effects when stimulated or inhibited.",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1038/s41467-022-35574-x"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1101/2023.01.03.521946"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, and list the hypothesized effects of stimulating or inhibiting them.",
    "model": "bing",
    "date": "2023-06-05",
    "answer": "According to an article on nature.com, one study identified 11 major projection neuron types with distinct morphological features and corresponding transcriptomic identities. Extensive projectional diversity was found within each of these major types. This diversity follows a set of generalizable principles that govern long-range axonal projections at different levels, including molecular correspondence, divergent or convergent projection, axon termination pattern, regional specificity, topography, and individual cell variability\u00b9. Another research paper published on nature.com states that the brain exponentially increases in size after the neural tube closes. Later in development, across brain regions, a series of similar neurogenic and gliogenic processes give rise to the...\u00b2. Unfortunately I could not find a third reference that meets all the criteria you requested.",
    "sources": [
      {
        "key": "1",
        "text": "https://www.nature.com/articles/s41586-021-03941-1 "
      },
      {
        "key": "2",
        "text": "https://www.nature.com/articles/s41593-020-00794-1"
      },
      {
        "key": "3",
        "text": "https://www.nature.com/articles/s41586-021-03223-w"
      }
    ]
  },
  {
    "question": "We need examples of specific, molecularly-defined populations of neurons in the brain we could target in order to enhance brain function. Please suggest three well-defined populations, list the function they are linked to, and list the hypothesized effects of stimulating or inhibiting them.",
    "model": "scite",
    "date": "2023-06-05",
    "answer": "Three well-defined populations of neurons in the brain that could be targeted to enhance brain function are:\n\n1. Sexually dimorphic neurons in the ventromedial hypothalamus (VMH) [1]. These neurons are linked to mating behavior in both sexes and aggression in males. Stimulation of these neurons in males has been shown to increase aggression, while inhibition of these neurons in females has been shown to decrease mating behavior.\n\n2. Neurons in the external segment of the globus pallidus (GPe) [2]. These neurons have been defined using molecular, anatomical, and electrophysiological criteria. Stimulation of these neurons has been shown to improve motor function in Parkinson's disease, while inhibition of these neurons has been shown to worsen motor function.\n\n3. Neurons in the central nucleus of the amygdala (CeA) [3]. This network consists of a heterogeneous population of inhibitory GABAergic neurons distributed across distinct subregions. Stimulation of these neurons has been shown to increase anxiety-like behavior, while inhibition of these neurons has been shown to decrease anxiety-like behavior.",
    "sources": [
      {
        "key": "1",
        "text": "https://doi.org/10.1016/j.cell.2013.04.017"
      },
      {
        "key": "2",
        "text": "https://doi.org/10.1523/jneurosci.4646-13.2014"
      },
      {
        "key": "3",
        "text": "https://doi.org/10.1002/cne.25332"
      }
    ]
  }
];